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CLINICOMYCOLOGICAL STUDY OF VULVOVAGINAL 
CANDIDIASIS 
Introduction   
Vaginal  Candidiasis  is a most common  fungal infection of the vulva 
and vagina  involving  nearly 75% of adult women during their lifetime. 
Vaginal Candidiasis is otherwise called as vaginal thrush. It  is caused by    
Candida species. Candidiasis of vulva  and  vagina is found to be the second 
most common cause of vaginitis after bacterial vaginosis. Candida albicans 
constitutes 85% to 90% of cases. 
Candida is a normal inhabitant of healthy mucosal surface of oral 
cavity, gastrointestinal tract and vagina. These are true opportunistic 
pathogens which utilise the host’s debilitated status and  gain access  to  the 
circulation and deeper tissues. However, some factors or conditions like 
prolonged antibiotics usage which alter the balance of micro organisms in 
the vaginal milieu, pregnancy, diabetes in which increased glycogen provide 
nutrition to the candidial growth, immunosuppressive drugs and  HIV 
infection may result  in an overgrowth of  Candida. Very young  and very 
old  are also at risk of getting the infection.  
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  The genus Candida is comprised of more than  200 species. The 
medically significant Candida species include Candida albicans, Candida 
glabrata, Candida tropicalis, Candida krusei, Candida parapsilosis, Candida 
lusitaniae, Candida kefyr, Candida stellatoidea, Candida guilliermondii, and 
Candida dubliniensis. Candida albicans is the most common opportunistic  
fungal infection which cause a range of mild superficial infections to life 
threatening systemic  candidiasis which occurs in immunocompromised 
patients. In recent years non Candida albicans species which are resistant to 
traditional antifungals are emerging. Nowadays candidiasis has become 
more and more severe due to the spread of HIV infection and the frequent 
use of  antibiotics and immunosuppressive therapies. Furthermore, the 
treatment of candidiasis is difficult due to the limited choices of antifungals.  
Classical clinical symptoms of vulvovaginal  candidiasis include 
curdy white vaginal discharge and vaginal itching. Making a diagnosis of 
vaginal candidiasis  includes performing a complete evaluation , detailed 
history and and physical examination, together with  pelvic examination. 
This consists of taking a swab from the vaginal secretions and  visualising it 
under a microscope to confirm  an  overgrowth of yeast.  Sometimes  
patients may get dysuria  and dysparunia. The surrounding tissue around the 
vulva and the vagina may become red and swollen. 
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Vulvovaginal candidiasis can be managed with a variety of antifungal 
agents, few of which are available over-the-counter. Although the way to 
clearly diagnose  vulvovaginal candidiasis  is to see the  pseudohyphae  
under the microscope, many women take medicines themselves based on 
their symptoms which favours infection with drug resistant species. Proper 
treatment usually results in complete  resolution . So in  view of these factors 
speciation and drug sensitivity of vulvovaginal candidiasis was done and the 
results were analysed . 
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VULVOVAGINAL CANDIDIASIS 
AIMS AND OBJECTIVES 
This study was done in adult females in the Department of 
Dermatovenereology at Tirunelveli medical college with the following 
objectives 
• To diagnose vulvovaginal candidiasis amongst female patients with 
genital pruritus and discharge pervaginum by clinical and laboratory 
methods including wet mount, 10%KOH mount and Gram’s staining. 
•  To identify the culture characteristics  and species prevalence of  
Candida species. 
• To study  the  drug sensitivity pattern of  vulvovaginal candidiasis 
those who were proved to have canidida infection by vaginal  smear 
study. 
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MATERIALS AND METHODS 
Our  study is a open prospective study which was conducted in the 
Department of  Dermato-Venereoleprology after obtaining clearance from 
Ethical committee of Tirunelveli Medical College with the co-operation of  
Department of microbiology, over a period of one and half years from 
January 2013 to July 2014. 
INCLUSION CRITERIA: 
1. All female patients aged more than 18 years with complaints of genital 
pruritus and discharge pervaginum attending the STD clinic of 
Department of Dermatovenereoleprology   
2. Those cases  proved  to have  candida  infection by  vaginal smear  for 
wet mount, KOH and Gram’s stain in the laboratory. 
 
EXCLUSION CRITERIA: 
1. Female patients aged less than 18 years. 
2. Patients already treated with antifungals. 
3. Vaginal smear negative for Candida.  
4. Pregnant women. 
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Female patients aged more than 18 years with genital pruritus and 
discharge pervaginum were included in the study. Oral and written consent 
in their local language was obtained before starting the study including 
consent for photographs. A detailed clinical history regarding the nature of 
discharge, duration of illness, recurrence, contact history, associated medical 
disorders like diabetes, drug history  and  contraceptive usage was taken. 
A thorough genital examination regarding sites involved, nature of the 
discharge and surrounding skin was done. Speculam examination was also 
done by keeping the patient in lithotomy position and self retaining bivalved  
Cusco’s  speculam was  inserted carefully in to the vagina to view the nature 
of vaginal discharge, presence of erosions and ulcers. Speculum examination 
was avoided in unmarried female patients.  
Vaginal discharge  was smeared in three separate slides. Wet mount, 
KOH mount, gram staining were done. The patients whose vaginal smear 
showed Candidial pseudohyphae as elongated structure with cell wall 
constrictions in KOH mount and Gram positive rods in Gram’s staining were 
chosen for study of culture, species identification and drug sensitivity. The 
vaginal swabs were inoculated in  Sabouraud’s dextrose agar and incubated 
at 37 °C for 48 hours. The candidial isolates were inoculated  in the Chrome 
agar and various species were identified based on the pigmentation. All the 
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isolates were subjected for antifungal susceptibility testing for fluconazole, 
itraconazole, voriconazole, clotrimazole, nystatin, miconazole and 
ketoconazole by disc diffusion method. The basic investigations like blood 
sugar, urea, creatinine, urine routine and complete hemogram were done to 
look for precipitating factors. The cases were treated with  antifungals 
according to the sensitivity and followed up after first and second week. 
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REVIEW OF LITERATURE 
Introduction 
Vulvovaginal candidiasis  is defined as infection of the vulva and 
vaginal mucosa caused by species of genus Candida. Candidial species are 
able to cause superficial lesions in both oral and vaginal mucosa when the 
equilibrium between fungi and the  host  change  in favour of the fungus
1
. 
The infection may be acute or chronic, superficial or deep and it has wide 
clinical manifestations. Most commonly it occurs secondary to a 
immunocompromised state.
2
 
Prevalence 
Vulvovaginal candidiasis(VVC)  is the second most common cause of 
vaginal infections next to  bacterial vaginosis  in Asia and U.S. This is the 
first common cause of vaginitis in Europe. It is estimated that 75% of 
women during the fertile period have at least one episode of vaginal 
Candidiasis.
3  
 Point prevalence studies indicate that the Candida species are 
found in 10-50% of healthy asymptomatic females of reproductive age group 
(sobel et al). Hermen Gardner said ‘Vaginitis cause more inconvenience than 
others’.  About 85-90%  of VVC is caused by Candida albicans.
4
 Other 
species are C.glabrata, C.parapsilosis, C.krusei, C.tropicalis 
C.guilliermondii. A study in U.S isolated candida from vaginal by PCR 
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method in 1316 women showed  Candida albicans 80.2%, Candida glabrata-
14.3 %, Candida parapsilosis-5.9% , Candida tropicalis-8.0% and  least 
percent of Candida krusei.
5
 
History: 
The first description for Candida infection is found in Hippocrates’ 
“Epidemics’ from 4
th
 century BC. Rosen von Rosenstein identified Candidial 
infection in paediatric patients and framed description in modern medicine. 
In 1844 , the fungus was isolated from the sputum of a patient with 
tuberculosis by Bennett. It was isolated from vaginal infections by 
Wilkinson in 1849.Later it was isolated from blood and brain by others. It 
was named as ‘Oidium albicans’ in 1853 by Robin. `Oidium albicans` was 
derived from the word Candida which describes the white Robe (Toga) worn 
by Roman senators.  Zopf in 1890 named it as Monilia albicans
6
. 
In 1923 Berkhout structured candida genus. Because of its genus name 
as  monilia,it is also called moniliasis. In 1978 Torulopsis glabrata was 
renamed as Candida glabrata. This name was internationally accepted in 
1954. The term candidiosis was used in U.K, France and Canada. 
Candidiasis is American English. The French word for oral thrush is Le-
Muguet which means’ lily of the  valley.
7
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Anatomy of female genital tract: 
Female genital system includes vulva, vagina, cervix, uterus tubes and 
ovaries. Vulva includes external genitalia and perineum. External genitalia 
includes mons pubis , labia majora, labia minora, vestibule, clitoris and 
vagina. With elevated levels of either endogenous or exogenous estrogen, the 
vaginal epithelium thickens due to glycogen storage. With decreasing  levels 
of estrogen, the lining  become thin and atrophic.
8
 
Labia majora: 
It is a fold of skin which encloses fat. Histologically, labia majora is 
covered with squamous epithelium consisting of sebaceous glands, apocrine 
sweat glands and hair follicles. 
Labia minora: 
It is a thin fold of skin situated inner to the labium majora. It  contains 
veins and elastic tissues and devoid of sebaceous glands and hair follicles. 
Clitoris: 
It is a rounded  subcutaneous structure situated at the junction of two 
labia minora and attached to the under surface of the pubic symphysis by 
suspensary ligament. It has well supplied nerve endings and is highly 
sensitive. 
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 Vestibule : 
It is a space situated between the anterior and inner aspect of labia 
minora. External urinary meatus lies just below the clitoris. Vaginal orifice 
lies below the meatal opening. 
Vagina: 
Vagina extends from cervix to hymen. Its anterior wall is 9cm in 
length and posterior wall is 11.5 cms. Vaginal portion of the cervix projects 
in to the upper portion of vagina forming anterior, posterior and two lateral 
fornices. Histologically it is lined by stratified squamous epithelium .Vagina 
is devoid of any glands. So the secretions from the vagina is derived from 
the transudation of epithelial cells. 
Structure of vaginal epithelium: 
The vaginal squamous epithelium is divided in to three layers. They  
are Superficial, middle and deep layers. 
 Superficial cell  layer have precornified cells  and fully cornified 
cells. 
 Precornified  cells are large hexagonal  wafer shaped cells with 
faintly  basophoilic cytoplasm and small pyknotic nucleus. 
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 Cornified cells are same like precornified cells but the cytoplasm is 
eosinophilic . 
 Middle layer consists of large ellipsoidal cells which are 
intermediate  between basal and  cornified  layer. 
 Deep layer cells are of two types. Basal cells and parabasal cells. 
These cells are small deep basophilic cells with large central 
nucleus. 
 These cells are under the influence of hormones like oestrogen and 
progesterone. Vagina of female newborn is cornified because of 
high estrogen content  obtained  from maternal estrogen. After 1-2 
weeks of birth the vaginal epithelium becomes thinner and  
remains  in the same state up to puberty. 
  During early proliferative phase, the vaginal squamous cells are 
maturing and cornification index which is the percentage of 
cornified cells rises. In late proliferative phase, the vaginal cells are 
fully mature and the cornification index is highest. During the 
secretory phase, the squamous cells are folded and become 
crumbled. Cornification index also falls. 
 During pregnancy, the cornification index is low in the first half of 
pregnancy and further reduction occurs in the later months of 
pregnancy.In the post menopausal phase, the vaginal epithelium 
becomes thinner and parchment like. 
13 
 
Physiology of normal vaginal secretions: 
In the reproductive age group, normal vaginal discharge consists of 
approximately 1-4 ml in 24 hours, which is white, transparent and odourless. 
It is more noticeable during pregnancy, at the time of ovulation and with oral 
contraceptive pills usage. 
Normal vaginal discharge is formed by 
 Transudation from vaginal epithelium and desquamated cells of the 
cornified layer. 
 Sweat and sebaceous gland secretions of vulva. 
 Bartholin’s gland  secretions 
 Mucous secretions from endocervical  glands. 
Vaginal acidity: 
A healthy adult women of child bearing age harbours lactobacillus, 
also called Doderllein’s bacilli which are Gram positive bacilli and sugar 
fermenting.
9 
 It converts the vaginal glycogen in to lactic acid accounting for 
the acidic vaginal pH. 
• Newborn – 5.7 
• Children- 6 to 8 
• Reproductive age group, pregnancy - 3.8 to 4.5 
• Menopause-7 
14 
 
Epidemiology:  
 Agent factors 
Candida is a yeast like fungus. Fungi are eukayotic organisms which 
possess rigid cell wall made up of chitin and it contains ergosterol. Chitin is 
a polysaccharide consisting of  long chains of N acetyl glucosamine. In 
addition to chitin the cell wall contains mannans which are the principal 
antigen component, betaglucans, and other polysaccharides. Basic 
differences  in the membrane sterols is the target for the selective action of 
antifungals. Candida species  are unicellular organisms that are  round to 
oval in shape and size ranges from 2 to 6micrometer. They reproduce by 
asexual methods to form budding blastoconidia and sexual methods by 
producing ascospores and basidiospores. Then the budding forms elongate to 
form pseudohyphae which resemble links of sausage. Pseudohyphae are 
elongated buds with cell wall constrictions. Cells that are elongated and 
ellipsoidal attached side by side to one another are referred to as 
psuedohyphae. True hyphae are characterized by cells in  cylindrical  shape 
and are separated by perpendicular septal walls. The hyphal forms  consists 
of conjoined cells that are divided by septal walls.  
Candida species  are found  in animals, human and  many food stuffs 
especially in packaged fruit juices.  In humans Candida species is commonly 
15 
 
found in GIT, oral cavity, genital area as commensals. So infection may be 
caused by endogenous invasion or acquired from external sources. 
Asymptomatic vaginal carriage is seen in 21-32% of healthy women. One 
recent study analysed  a group of females  and frequently  screened them 
over one year.  No colonisation was observed in 30%,  70% were colonised 
at least one occasion, persistent colonisation was found in 4%. Higher rates 
are found in pregnant women associated with high Lactobacillus 
colonisation, diabetes melitus and post antibiotic treatment.
10
 Candidiasis is 
the most common opportunistic fungal infection encountered in 
immunosuppressed  patients (spinillo et al).
11 
 Recent studies demonstrated 
the ability of candida to become  resistant for  common  antifungals. 
Nomenclature  of candida 
Order    : Cryptococcales 
Class    :  Blastomyces 
Genus   : Candida 
Species   
 Candida albicans,  
 Candida glabrata 
 Candida krusei 
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 Candida tropicalis 
 Candida parapsilosis 
 Candida guiliermondii 
 Candida kefyr/Candida stelloidea 
 Candida rugosa 
 Candida dubliniensis 
 Candida vishwanathii 
Candida lusitaniae 
About 200 species of Candida are discovered so far of which Candida 
albicans  is the most common organism. Only less than 10  non Candida 
albicans species are associated with infection. These species can be 
differentiated by colony characteristics, microscopy, biochemical reactions  
such as fermentation &sugar assimilation and growth in different media.
12 
Candida albicans: 
There are 2 serotypes of C. albicans, type A and B based on their 
differences between mannan components of cell wall. Type A is antigenic 
similarities to C.tropicalis. Type-B C.albicans is commonly found in 
immunocompromised  persons in Europe. Type A, B were common in US. 
Type A is also found  in blood culture isolates.
13
 Other Candida species apart 
17 
 
from  C.albicans which were  previously thought  to be  non pathogenic  are 
now emerging as agents of infection. 
C. glabrata infection is commonly seen in adults and elderly than 
children. C.tropicalis is most commonly encountered in patients with 
hematological  malignancies especially in conditions with neutropenia.
14 
 
Mouse models  and some  human studies  showed  C.tropicalis  in tissues 
surrounded by necrosis which  indicates  the organism  can invade the tissue 
efficiently. This phenomenon is due to the expression of  aspartyl proteases 
and acid proteinase  which are the virulence factors found in Candida 
organisms.
15
 C.krusei  is associated with  resistance to  azole antifungals. It 
has ability to grow in vitamin free media.  C.parapsilosis  is the primary  
cause of  fungemia in  neonatal intensive  care units and in blood cultures 
due to its selective growth in  hyperalimentation solution  and also its ability 
to grow in  intravenous catheter. 
Virulence factors of Candida species: 
 Adhesin: 
They are the fungal surface molecules which adhere to the  host 
buccal, vaginal, dermal epithelial cells, endothelial cells, oral and GI tissues  
and  some inert substances such as indwelling medical catheters. Several 
adhesins are discovered so far. They are  mannans and chitin.
16
 Mannans  
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are  mannoproteins  which are  proteinaceous  substances. Different 
Candida species have different adhesins. 
Biofilm formation: 
After initial adherence, the fungi grow in multiple colonies  forming 
biofilm. Biofilm is composed of proteins and carbohydrates which  are 
responsible for the poorer response to antifungal drugs and also difficulty in 
clearance by host immune system. It can be demonstrated in all Candida 
species especially C.albicans. Biofilm formation on catheters and prosthetic 
valves can cause systemic disease.
17
 
 Enzymes  with  hydrolytic activities  in Candida species play major 
role in pathogenesis. They are aspartyl proteinases, 
serineproteinases, proteases, lipases, phospholipases, esterases  and  
phosphatases. Hyphal tip with phospholipases exhibit greater 
invasiveness. 
 Toxins which  are  glycoprotein  extracts  of Candida cell walls are 
lethal, pyrogenic  and  induce anaphylactic shock. 
 Complement receptors-Candida albicans possess C3b which binds 
to complement as well as fibrinogen there by affecting the binding 
of neutrophils which in turn influence  phagocytosis. 
 Phenotype- switching : 
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It is the ability of candida to switch reversibly to different colony 
phenotypes ranging from unicellular budding yeast to pseudo hyphae and  
true hyphae. The colony morphology changes from smooth to rough and 
fuzzy. This phenomenon is first described by Slutsky et al in 1985, 1987. 
This is analogous to phase variation in bacteria. It expresses fungal  
plasticity and  adapt the organism to various  anatomical sites in human 
body. This property helps the organisms to evade the host’s defense system. 
Host factors: 
Predisposing factors:- 
1. Pregnancy have 30-40% of high risk especially in third trimester.
18,
 
Certain  changes in the levels of female sex hormones, such as excess 
estrogen, make a woman more likely to develop a yeast infection. 
Recurrent infections are  also more likely. There is no clear evidence that 
treatment of asymptomatic candidal vulvovaginitis reduces the risk 
of pretem delivery in pregnancy. Furthermore, the acidic nature of the 
pregnant vagina  suppress the growth of other microorganisms  that are  
naturally inhibitory to Candida. Although the high pH of 6-7 augments 
the initial attachment of the organism to the vaginal epithelia, the 
formation of  germ tubes and the development of mycelia are favoured 
by acidic vaginal ph of less than 5. 
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2. Diabetes mellitus is one of the predisposing factor for recurrent 
vulvovaginal candidiasis.  Elevated levels of  blood glucose  enhances  
the ability of  C. albicans to bind to vaginal epithelial cells. Diabetes 
mellitus is believed to increase the propensity by raising tissue glucose, 
decreased phagocytosis, and altered yeast adhesion.
19
 
3. High estrogen content in oral contraceptive pills (>50µg) increases 
glycogen content  in vaginal epithelial cells  which  acts as  good source 
of carbon  needed  for Candida for its growth and germination.
20
 This 
hormone also accelerates the formation  pseudohyphae. Progesterone, 
lactation are safe factors. 
4. Drugs: 
• Frequent  antibiotics clears the normal protective vaginal flora 
there by facilitating Candidial colonisation. The possibility of 
infection increases with the total duration of antibiotic use, but 
not related to a specific group of antibiotic.
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• Systemic steroids increase the susceptibility to candidiasis by 
diminishing the immune function. A study done at tertiary care  
centre showed 19.83% association between corticosteroids and 
vulvovaginal candidiasis. 
4 Tamoxifen usage in post menopausal women also enhances candidial 
infection 
21 
 
5. IUCD, diaphragm, spermicide, douching, perfumes and use of feminine              
hygienic products  will produce  minor trauma  to the vulva  and alter the 
vaginal  bacterial flora.  Douching  is also a risk factor in females with 
recurrent vulvovaginal candidiasis  caused by  Candida glabrata.
22
 
6. Endocrine diseases like, hypothyroidism, hypoparathyroidism, Cushing 
syndrome and polyendocrinopathy  are associated with increased  
susceptibility to infection. 
7. Immunosuppressive states like HIV infection, neutopenia, organ 
transplantation  and  congenital  immunodeficiencies express defective 
killing by neutophils  and macrophages thereby increasing the 
susceptibility to infection 
8. Occlusion and maceration of skin due to tight dressings: 
Perspiration associated with poorly ventilated  underwear or tightly 
fitted clothes  increases  moisture  and  local temperature. Mechanical 
irritation of the genital area by clothing or sexual intercourse may also 
predispose to infection. 
9. Nutritional factors:- 
Nutritional   deficiencies may alter host  defense mechanisms or 
epithelial barrier integrity, allowing increased adherence or penetration. 
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• Iron deficiency causes oral candidiasis but unbound Iron enhances 
C. albicans growth. Vitamin A  deficiency  affects  keratinisation. 
Vitamins B complex, vitamin C and folic acid are associated with 
higher rate of infection.  
• Zinc deficiency causes chronic GI disease which can lead to 
recurrent vulvovaginal candidiasis. 
• Protein deficiency results in impaired host defense. 
Genetic predisposition: 
Women those who are non secretors of Lewis antigen, a glycoprotein 
that inhibit the binding of Candida to  the vaginal mucosa  are vulnerable to 
recurrent  vulvovaginal   candidiasis.
23
 Genetic polymorphisms ,   inherent          
hypersensitivity  to yeast  are  also  risk factors.
24,25 
 In healthy women, the 
vaginal epithelial cells show some anti Candida activity which is low in 
patients with recurrent vulvovaginal candidiasis.
26
 
Atopy  
Women with recurrent vulvovaginal candidiasis(RVVC)  were found 
to be associated with atopy in some instances. A study on ninety five patients  
with RVVC were compared with 100 controls, it showed 74% incidence of  
allergic rhinitis against only 42% in control group.
27
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 Few case  reports  showed  high titres of eosinophils and Candida 
specific IgE  in vaginal washes indicating that a local immune response may 
play some  role in RVVC.
28,29 
 However, the patients with RVVC with 
evidence of  IgE or eosinophils  in vaginal washes is much lower than the 
healthy females.
30,31 
10. Sexual  factors:
 
Orogenital  sex may facilitate the introduction of microorganisms.
32 
The role of sexual transmission is controversial, even if some male sexual 
partners  experience a  transient erythema,  itching  and  burning  sensation 
in the  genitals few minutes  to hours following  sexual intercourse. A 
randomized controlled trial evaluated the outcome of treating male sexual 
partners with  ketoconazole  had similar recurrence rates as that of the 
untreated partner groups  at six months and one year.  
Serum factors: 
Substances  in the serum such as transferrin and clumping factor 
enhances germ tube  and mycelia  formation thereby  facilitating invasion.
33
 
These  factors also cause inhibition of  T cell function  which  can be 
reversed by antifungals 
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HIV and vaginal candidiasis: 
Acquired immunodeficiency syndrome (AIDS) is a chronic disease 
primarily affecting the human immune system caused by the human 
immunodeficiency virus (HIV).  It  is a two single stranded  RNA virus 
which gradually  reduces the normal  functioning  of the immune system and  
thereby, making  the individuals  vulnerable  to infections and other  
diseases. The virus initially  destroys  CD4 T-lymphocytes which helps  to 
organize the immune system’s response to infection and disease. The  CD4 
cell count is considered as a marker to determine the progression of the 
disease. Patients with a CD4 cell level less than 200 cells per  microlitre  
have progressed to AIDS. Another name for CD 4 cells is T-helper cells. 
CD4 cells are made in the lymph nodes , spleen, and  thymus.  In addition to 
other tests, the CD4 count is necessary for staging  HIV disease, to  predict  
the progression  and  guidance to treatment. Complications of HIV  are less 
with higher CD4 count  and  life expectancy is more. 
Vulvovaginal  candidiasis (VVC)  is one of the most common fungal 
infection which recurs frequently in females with human immunodeficiency 
virus (HIV) infection. Inspite of only rare chances of systemic fungal 
infection and  mortality, it is essential to prevent and treat candidial 
vulvovaginitis for improving the quality of life of HIV positive patients. 
Oral,  esophageal  and vulvovaginal candidiasis  are the  common forms of 
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Candida infection in HIV positive  individuals. They are the  indicators  of  
severity of immune deficiency and  forerunners of  systemic opportunistic  
infections. Prevalence of vaginal Candidiasis  is directly  propotional  to the 
immunodeficiency in HIV positive individuals .  Immuno suppression  and  
frequent usage of antibiotics for various bacterial opportunistic infections are 
the reasons behind this.  A  cross-sectional study of  833 HIV positive and 
427 HIV negative  women , the yearly incidence of  vaginal candidiasis  was 
similar (9%) in the 2 groups.  A study on 205 HIV positive women, the risk 
of  developing symptomatic VVC is increased 5-6 times for those with CD4 
count of <200 cells/microliter. The rate of candidial  colonization of vagina 
in  immunocompetent (CD4 cells>500) HIV positive women  and  HIV 
negative women  was the same,
34
  although the relationship between  HIV 
infection  and vulvovaginal candidiasis  remains uncertain. There  is no 
much difference in the symptomatology in HIV positive and negative 
women.(Spinillo et al). Symptomatic vulvovaginal candidiasis  is more 
common in HIV positive patients  and  directly  proportional to the severity 
of  immunosuppression.  Symptoms of vulvovaginal candidiasis  generally  
get worsened  during  menstruation because the hormonal changes make the 
vaginal mucosa  suitable  for fungal growth. In addition, in HIV positive  
women, chronic exposure  to  systemic  azole  antifungals  results in growth 
of non Candida  albicans  species in the  the vagina.  
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The individual Candida species  affecting  patients  with HIV infection 
are not different from those in other immunosuppressed hosts.
35
 C 
dubliniensis is frequently identified in HIV positive  persons, though it is 
presently impossible to differentiate from C. albicans in its clinical 
presentation.
36,37
 .There are no apparent differences in the virulence of 
organisms  isolated from HIV positive  or HIV negative persons. Recurrence 
can result from the same or from different species  of Candida.
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 Reinfection 
with different species of Candida is more common in persons with previous 
antifungal therapy and low CD4 lymphocyte counts. Candida dubiliniensis is 
commonly occurring in HIV positives. A study conducted by Deepa babin et 
al revealed 1.6%  of  vaginal candidiasis  belongs to C.dubliniensis.  
The  development of mucocutaneous candidiasis depends on many 
factors. The degree of  immunosuppression is the vital factor. Other host 
factors responsible for the protection against  Candida infections include 
blood group secretor level such as presence or absence of specific Lewis 
antigens, rate  of salivary flow, antimicrobial activity of saliva, the epithelial 
barrier integrity, presence of normal bacterial flora, and  the local 
immunity.
39
 Several studies suggest an impaired  host immune response to 
Candida  in persons with HIV infection. Plasma  HIV-1 RNA levels are  
found to be elevated in patients  with higher incidence of  mucocutaneous 
candidiasis and colonization with Candida.
40
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Refractory candidiasis: 
Refractory vaginal candidiasis  is fairly  less common.  It  is defined as  
the failure of  response to antifungal drugs  for a standard  time  duration  
that is for 14 days with suitable doses.
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 Anti fungal resistance is classified 
as clinical and  invitro resistance. Clinical resistance is due to non 
compliance with the drug regimen that leads to low serum and tissue levels 
of the drug. This is most common in HIV positive patients due to profound 
immunosuppression where a high dose antifungals are unable to eliminate 
the fungus. 
Invitro  resistance is  subdivided  in to primary  and  secondary. In   
primary resistance  the organism is  naturally  resistant  to  antifungals. Eg. 
C.krusei  to fluconazole . In secondary  or acquired  resistance  the organism 
becomes  resistant during  the course  of  the treatment. This type is more 
common in HIV positive individuals. Fluconazole  resistant cases are viewed 
with particular attention  due to  considerable morbidity and  often requires 
alternate parenteral antifungals  for the treatment. Refractory candidiasis 
usually occurs in patients with advanced HIV disease with CD4  counts  less 
than  50 cells/µL who were already treated with  antifungal therapy for 
prolonged period.
42 
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Refractory candidiasis  is hard to treat and gradually become 
unresponsive to therapy . The most significant step is to decide what 
medications and dosages have been tried and whether the patient’s adherence 
to therapy is sufficient. Removal of any interacting drugs or increasing the 
drug dosage of the antifungals may  cure the disease in some persons. 
Amphotericin B, itraconazole, or  flucytosine are the alternative therapeutic 
strategies. Other options for the treatment of  fluconazole-resistant isolates 
include voriconazole, micafungin, caspofungin, and anidulafungin. 
Antiretroviral therapy must  be optimized in patients with refractory 
candidiasis. Treatment with protease inhibitors is found to be useful in the 
clinical improvement in difficult-to-treat cases.
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 Protease inhibitors have 
been shown to inhibit Candida  secretory aspartic proteases, indicative of 
direct antifungal activity against Candida. The duration of antifungal 
treatment for refractory disease depends on the response, but in general a 
course of 14 days is given for vaginal disease. Higher relapse rates seen in 
persons with refractory disease, and suppressive therapy is commonly 
required. In difficult cases, weekly therapy of  2-3 times a week or daily 
suppressive therapy may be required to avoid relapse. 
The  incidence of systemic candidiasis in AIDS is  probably <1%. 
Patients  who develop systemic candidiasis  are known to have risk factors 
like, chemotherapy, neutropenia, indwelling intravenous catheter and 
parenteral alimentation.
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 The  occurrence of invasive candidiasis in HIV 
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patients is rare. The pathogenesis of invasive candidiasis  involves 
discontinuity  of a mucosal  surface barrier with subsequent haematogenous 
dissemination secondary to macrophage  and neutrophil  dysfunction in 
conditions that are not distinctive  feature  of HIV disease.            
In a  published study  of 14 cases of  Candida meningitis  in HIV  
positive  patients, a history of at least one predisposing factor was noted in 
ten of the patients, nine  of them were intravenous drug abusers. Of interest, 
4 patients had no risk factors.  The HIV positive patients with 
Candida meningitis can be treated with prolonged suppressive therapy with 
fluconazole with a regimen similar to that used in the treatment of 
cryptococcal meningitis. 
HAART is the only best method of  reducing  the incidence of 
mucocutaneous candidiasis. Most  studies demonstrated, the use of  HAART 
reduces the rate of colonization and severity of clinical manifestations.
45
 This 
is correlated with reduction in HIV-1 RNA levels in the plasma. The other 
effective interventions include smoking cessation, the treatment of 
opportunistic infections, good hygiene, avoidance of unwanted antibiotics, 
steroids, and antifungal drugs. So the most important way of  preventing 
mucocutaneous candidiasis is improvement of immunodeficiency associated 
with  HIV infection . 
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Immunology: 
Candida species are commensal as well as opportunistic pathogens of 
mucosal tissues. Both innate and acquired immunity play a vital role in 
keeping  the organism  in the commensal state and preventing it to enter in to 
the systemic circulation. Neutrophils plays important role in the  protection 
against systemic infections, whereas cell-mediated immunity (CMI) by Th1- 
CD4+ T-lymphocytes aids protection against mucosal infections. Candida-
specific antibodies are controversial in the protection against infection. Some 
studies done on mucosal innate resistance recently established epithelial cells 
from vaginal lavages and saliva of healthy individuals inhibit the growth of 
Candida in vitro. Oral epithelial cells obtained from HIV positive candidates 
suffering from oral candidiasis have significantly reduced activity. So these 
studies indicate some protective role for the epithelial cells and suggesting 
that immunity to Candida is site-specific and compartmentalized.  
The level of innate immunity to pathogenic fungi is high in most 
humans as evidenced by the fact that the fungal infections are usually mild 
and self limiting. The intact skin and mucosal surfaces are the primary 
barriers to infection. Epithelial cell turn over, fatty acid content of the skin, 
low ph of vagina are the important factors of host resistance. Bacterial flora 
of the skin and mucosae compete with fungi and inhibit their unhindered 
proliferation. Alteration in bacterial flora and any break in the natural barrier 
facilitate infection. 
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The outcome depends on the virulence of organism and size of 
inoculam and adequacy of host defenses. Cell mediated immunity provides 
protection against pathogenic Candidial colonization. Phagocytosis by 
neutrophils is the primary mode of elimination of infection. Some evidences 
showed that antibody along with complement play a role in eliminating fungi 
from the body. 
Candida antigens: 
1. Cell wall antigens 
2. Cytoplasmic antigens 
These antigens are useful for serological applications i.e agglutination 
reactions. Mannan is the major antigenic component of cell wall. Subtle 
variations in the linkage and side chains of mannose residues led to the 
serotyping and speciation. The glucan polymers which present in more 
abundance is immunologically less active. The number of antigenic 
components in broken cells is also significant. 
Pathogenesis: 
Most of the candidal species produce virulence factors including 
protease factors. The species which do not have the virulence factors are less 
pathogenic. The ability of yeast forms to adhere to the host’s epithelium is a 
crucial step in the  hyphae  formation  and  pathogenic  tissue invasion.  
Elimination of the competing bacteria from the skin and mucosae  results in 
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reduced  nutritional and environmental competition that favours the growth 
of Candidal organisms. 
Additional researches proved that cytokines and interleukins have a 
significant role in candidial infection. In keratinocytes, C albicans  
phospholipomannan provokes  an inflammatory response through toll-like 
receptor 2. Candida albicans reduces  the expression of interferon-gamma–
inducible protein-10 in human keratinocytes.
 
These factors explain innate 
defenses against candidal organisms. Interleukin 12 receptor β1 deficiency 
predisposes to candidiasis, most commonly of mucocutaneous candidiasis. 
 
Steps in pathogenesis: 
 Adherance to epithelial  endothelial surface 
 Invasion 
 Host immune response 
1) Adherence: 
C. albicans have more affinity towards vaginal epithelial cells 
Order of affinity: 
C.albicans>C.tropicalis>C.parapsilosis 
Factors influencing adherence: 
 Local vaginal pH: 
Candida adhere to the vaginal mucosa even if the pH is acidic. 
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 Removal of competing bacteria leads to increase in the number of 
yeasts thereby facilitating invasion. In some areas like web spaces the 
bacteria especially gram negatives act as co pathogens rather than 
competitors. 
 Nutrients: 
 Glucose is the crucial factor in maintaining balance between 
Candida and bacteria in saliva . If there is high glucose as in diabetes 
there is only low level of competition exists between them and 
Candidal invasion occurs very easy. 
 Hormonal level- Estrogen increases the glycogen content of the 
vaginal epithelial cells  thereby increases the  affinity. 
 Presence of lg A interfere with adherence 
 Cell surface hydrophobicity- germ tube formation is enhanced by 
hydrophobicity. Adherence results in colonization at the local site or it 
invades deeper tissue and cause symptomatic disease. 
2) Invasion: 
During active infection, yeast form is converted in to hyphal form. 
Phospholipases  at the tip of hyphae  is related to greater  invasiveness 
compared to yeast  form.  Hyphae is  larger than yeast. Hyphae which are 
longer than 200 micrometer are more resistant to phagocytosis. Invasion is 
aided by various enzymes like proteinases which cleave the peptide bonds. 
Phospholipases enhance invasion by proteolysis in keratinocytes. Aspartate 
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proteinases are collagenolytic. Another study revealed elevated levels of 
hyaluronan in patients with RVVC, which is associated with severe itching , 
burning and vaginal discharge. 
Host immune response: 
Candidial infections stimulate both Cell mediated[CMI] and humoral 
immune responses. But CMI is the first line of defence.CMI includes 
activation of neutrophils, mononuclear leucocytes, keratinocytes and 
dendritic cells. Candida albicans interact with the major antigen presenting 
cells i.e., dendritic cells. The dentritic cells stimulate Candida albicans 
specific lymphocyte proliferation which recognize them via mannose 
receptors. The glycosilated portion of Candida mannoprotien 65 (MP65) 
stimulates Th1 responses secreting cytokines like IL2,IL12,TNF alpha  and  
IFN gamma the production. T cell activation via toll like receptors leads to 
cytokine release and inflammatory cascade proceeds. 
In addition to cell mediated  immunity, humoral immunity also act 
against Candida. Antibodies have been recovered from experimental animals 
with vaginitis. IgM and IgG antibodies are found in mucocutaneous 
candidiasis.  Anti Candida IgE antibodies have been demonstrated in patients 
with allergy.
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 witkin et al 1989 demonstrated  IgE antibodies in women with 
vulvovaginitis indicating a possibility of type 1 hypersensitivity in the 
pathogenesis of vulvovaginitis.  Local immunity  also plays an  important 
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role in defense against Candida. IgA  antibodies have been  demonstrated  in 
vaginal fluid.
46 
A study in 28 patients with RVVC showed T cell dysregulation with 
increased production of IFN ϒ in RVVC patients. This can be exacerbated 
by increased level of estrogen in follicular phase of menstrual cycle.
47
 Some 
patients responds to hyposensitisation with Candida antigen given as a 
course of few weeks to months which exhibits the role of hypersensitivity 
reaction in the pathogenesis. 
There is another emphasis that Th1 and Th2 response to candida cross 
regulate each other. If there is increase in antigen load, there may be 
induction of Th2 response of inhibition of normal protection aided by Th1 
activity. 
Histopathology : 
• H&E staining shows spongiotic and subcorneal pustular dermatosis 
like picture with mixed dermal infiltrate. 
• Fungal organisms are demonstrated within stratum corneum by 
special stains like Gomori methenamine silver stains. Spores appear 
as 3-6  micrometer  round to ovoid  in shape. Pseudohyphae are 2-4 
um, septate, branching at right angles. Constrictions are present at 
the site of septations. 
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Clinical features: 
Clinical features ranging from asymptomatic to severe vulvovaginal 
candidiasis. 
Clinical classification:  
Centers for disease control and prevention classified VVC in to two 
groups.
48 
Uncomplicated VVC: 
• Single  episode or less than 4 episodes in a year.  
•  Mild  or  moderate symptoms 
• Causative organism  is Candida albicans . 
Complicated VVC: 
• Recurrent episodes- 4 or more episodes  per  year  
• Severe symptoms  of  vulvovaginitis 
• Associated  with  pregnancy, poorly controlled  diabetes and  HIV 
infection 
• Caused  by the  non Candida albicans  species  
Acute Vulvovaginal Candidiasis: 
Symptoms                
• Vaginal pruritus 
• Soreness/Burning pain 
• Vaginal discharge 
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• Dyspareunia 
• Dysuria as the urine come in contact with the inflammed vulval and 
vaginal mucosa  
Signs: 
• Erythema, 
• Fissuring  
• Edema of vestibule , labia 
• Thick white curd like or ‘cottage cheese like’ vaginal discharge 
adherent to the walls of vagina, labia which bleeds on removal. 
• Maceration in the adjacent skin 
• Satellite pustules in the perineum, groins and thighs. 
Chronic VVC: 
Symptoms: 
 Severe pruritus 
 Burning sensation 
 Irritation 
 Pain 
Signs:- 
 Lichenification of Vulva 
 Greyish sheen made up of epithelial cells and organism cover the 
area. 
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Differential diagnosis: 
Infectious   conditions: 
 Recurrent bacterial vaginosis: 
It presents as profuse greyish white thin homogenous discharge 
lining the vagina and smear positive for clue cells. Vulval  
irritation is mild. Episodes are not  related  to menstruation. 
 Trichomonas vaginalis infection: 
Trichomonas vaginalis is distinguished from VVC by the 
presence of copious greenish frothy discharge with fishy odour 
associated with  intense pruritus. Wet mount of vaginal smear show 
motile Trichomonads.  Episodes occurs  most commonly in the post 
menstrual period.  
 Chlamydia infection is distinguished by the presence of cervical 
erosion, discharge, fornicial tenderness. 
 Recurrent genital herpes present  with either vesiculation or painful 
superficial ulcers with polycyclic borders. Tzanck smear show 
multinucleated giant cells. 
 Genital scabies:  nocturnal pruritus, family h/o itching, excoriated 
papules over the genital region, around the umbilicus ,medial thighs 
and around the areola. 
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Non infections conditions: 
 Allergic vulvitis 
 Chemical vulvitis  
 Contact dermatitis: 
The diagnosis is based on the patient's detailed history and physical 
examination. Pruritus is the general symptom. An acute reaction may 
develop as a result of exposure to a  potent irritant  that  involves  the  
mucosa, leading to burning sensation, pain followed by oozing, which may 
lead to secondary infections. 
 Atrophic vaginitis- 
Women with mild to moderate vaginal atrophy (60-90%)    may 
notice a slight decrease in vaginal lubrication. Vaginal dryness, 
dyspareunia, Postcoital burning, leucorrhea and occasional spotting 
are other features. The vagina appears thin, with occasional 
petechiae and diffuse erythema and with reduced vaginal rugosity.  
pH   is 5-7. A serosanguineous discharge may be present. A wet 
mount often shows white blood cells and a paucity of Lactobacillus. 
 Idiopathic vestibulitis syndrome 
 Desquamative inflammatory vaginitis 
 Erosive lichen planus 
 Dermatosis like Eczema, Atopy and psoriasis 
 Physiological leucorrhea: 
40 
 
It is a natural discharge secreted by the vaginal epithelia due to some 
hormonal and metabolic, changes in the body itself. This is normally 
observed in females of child-bearing age group. The discharge is normally 
colourless, sticky, not offensive or foul smelling.. It may not normally stain 
the clothing or just dampen. There might be a feeling of weakness and 
fatigue but there is no burning, itching and erythema. 
Laboratory diagnosis: 
 The diagnosis of VVC is often made clinically and treatment can be 
started empirically. In clinically doubtful cases we opt for 10%KOH mount 
and Gram’s staining. 
 Vaginal pH- vaginal swab should be taken from lateral vaginal wall & 
placed on pH paper. In Candidiasis, the pH is between 3 and 4.5. 
Contamination with blood, cervical mucus, semen and local medication 
interfere with interpretation of results. 
Direct microscopy 
Direct microscopical examination of clinical specimens  reveals 
budding yeast cells called blastoconidia,2-4 µm in diameter with 
pseudohyphae showing regular points of constrictions resembling links of 
sausage.True septate hyphae may also be produced by C.albicans and C. 
dubilinensis. 
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 Wet mount-saline preparation: 
A sample of vaginal secretion is smeared on a glass slide, a drop of 
saline is added,  coverslip applied over it and seen under microscopy for 
presence of pseudo hyphae.  It can detect 40-60% of symptomatic cases. 
 10%KOH mount-vaginal smear is made on a glass slide and  one drop of 
10% KOH is added. Apply coverslip over the smear.  Gentle warming of 
the slide or addition of dimethyl sulfoxide causes rapid clearance of the 
keratin and other cellular debris, leaving the fungal element intact. 
Microscopic visualization reveals budding yeasts and pseudohyphae. It  
has 70% sensitivity. 
 Calcofluor  white  stain  fluoresces  under filtered UV light as bright 
green  because of its binding to polysaccharide in the chitin of the fungal 
cell wall. 
 Gram stain- Thin vaginal smear is made. Methyl violet is added and 
washed after I minute. Then Gram’s iodine is added to retain the primary 
color. Then  acetone or alcohol is added to decolorise for few minutes. 
Finally carbol fuschin 1:20 dilution is added as a counter stain. After 
washing and drying it is seen under microscopy. Yeasts and pseudo 
hyphae appear as Gram positive elements. It has 65-68% sensitivity. 
 Vaginal swab smear stained by methyleneblue & examined 
microscopically shows presence of regular blastospores  as well as 
pseudo hyphae. 
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 H&E Stain  and  Gomori’s methenamine  silver stains  demonstrate 
fungal elements in tissues. 
Germ tube test :-  
This test proves yeast germination. Suspected colonies are incubated 
in sheep or normal human serum at 37
o
c
  
for 2-3 hours. A drop of 
suspension is spread on a slide and examined under microscope. Germ tubes 
are seen as long tube like projections extending from the yeast cells. There 
is no constriction at the point of attachment of pseudohyphae. This test is 
known as REYNOLDS BRAUDE phenomenon. 
Chlamydospore formation: 
Yeast  produces  chlamydospores on  cornmeal  polysorbate 80 Agar 
at 22
o
c to 25
o
c in 48-72 hrs. Chlamydospores are refractile thick walled cells 
produced under nutrition poor, oxygen deprived conditions at low 
temperatures.
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Yeast assimilation test : 
It represents safest identification of non-candida albicans species 
based on the ability to assimilate coal hides (organic compounds). Agar 
plates with Candida on which paper discs impregnated with different 
carbohydrates are placed. Candidial growth around a particular disc is an 
indication for assimilation of that particular carbohydrate. 
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Fermentation reactions: 
It is done in Liquid media supplemented with different carbohydrates 
and colour indicator. Durhams tube is used to indicate gas production in the 
fermentation reaction.
50
 Acid production and pH changes are indicated by 
various colour changes. 
Culture: 
Sabouraud’s dextrose agar [SDA] otherwise called Nickerson’s 
medium is the most common medium used for cultivation of fungi, moulds 
and yeasts. It contains glucose, neopeptone, poly peptone agar and  supplied  
with  chlorheximide,  chloramphenicol  and  gentamycin  to prevent bacterial 
contamination.  Glucose provides carbon and peptone agar provides 
nitrogen. The pH of the media is slightly acidic[5.6].The colonial and 
microscopical morphology is of little clinical importance. Vaginal swabs are 
inoculated in SDA agar and incubated at 25°c and 37°c .The colonies appear 
in 3-4 days. Most of them produces smooth creamy white colonies. Some 
produces wrinkled dull colonies. 
 Candida  albicans   produces  cream coloured smooth pasty 
colonies 
 Candida tropicalis  produces  cream coloured to white, glistening to 
dull, smooth or wrinkled colonies with mycelial fringe. 
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 Candida glabrata produces smooth cream, coloured , glistening, 
small colonies. 
 Candida  parapsilosis  produces  creamy colonies in lacy pattern. 
 Candida kefyr  produces smooth soft creamy colonies. 
 Candida guillermondii  produces  thin flat, glossy, cream to pink 
glistening smooth wrinkled colonies. 
 Candida krusei  produces  flat dull dry smooth or wrinkled colonies 
with lateral fringe. 
HI chrome differential agar(HIMEDIA): 
CHROM agar is rapid  plate based  test  for isolation  and  
identification of  various Candida species simultaneously.
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 It contains 
chromogenic material which is acted upon by  distinct enzymes secreted  by 
different Candida species to yield a characteristic colony colour. It contains 
glucose, peptone, agar, chromogenic mix with the pH adjustment of 6.1. It 
should be stored in 2-8degree C away from direct light. Sample has to be  
inoculated  and incubated at 37
o 
c for 48 hrs. 
Characteristics of various Candida species: 
C.albicans:  
C.albicans grow as a medium sized, smooth, green to dark metallic 
green colored wet colonies at 48 hours. 
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C. krusei: 
It grows as a large, flat, spreading, rough to crenated , pink coloured 
dry colonies. 
 
C.tropicalis: 
Medium sized smooth medium to dark metallic blue coloured colonies 
appear  in 24 hours. 
C.glabrata : 
It produces medium sized  pink coloured wet colonies with darker 
mauve center.  
Other species – white to pink coloured  colonies 
Non culture methods:- 
Differentiation of diverse species of candida in laboratories is done by 
time consuming unreliable methods. Discovery of PCR overcome this 
problem. 
 
Serological tests: 
 Antibodies to mannan proteins 
 Gel immunodiffusion, immunoelectrophoresis, ELISA detect 
antibodies against enolase and heat shock proteins. 
 Detection of Arabinitol in the body fluids of infected persons. 
 
46 
 
Polymerase chain reaction[PCR]: 
Polymerase chain reaction is a method by which an area of DNA 
molecule is chosen and amplified. This method is very expensive but much 
more specific  than conventional methods. It can detect <10 yeast  colonies 
in the vaginal swab. So it is highly sensitive  but not suitable for 
differentiating the asymptomatic candidiasis from others.
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 Candida albicans 
DNA can be measured by PCR for the diagnosis of invasive candidiasis. 
Modifications of PCR 
 Single, direct PCR 
 Multiplex PCR-this test is much faster and more sensitive. 
 PCR with dot blot hybridization-This method detect candida in 
blood culture samples targeting specific rRNA sequences. 
TREATMENT 
 A wide variety of drugs are effective for the treatment of candidiasis. 
The mainstay of treatment of  vulvovaginal candidiasis is the antifungals.An 
antifungal agent is a drug that selectively eliminates fungal pathogens from a 
host with minimal toxicity to the host. Besides antifungal agent clinical 
response is determined by the severity of disease and patient adherence to 
the treatment and the pharmacological properties of the drug. Treatment of 
vulvo vaginal candidiasis is very simple and most of the strains respond to 
therapy.  Randomized studies show little  difference  between systemic and 
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topical therapy. Milder forms can be managed with topical therapy. 
Moderate and severe cases needs systemic therapy. 
The discovery of antifungal agents has lagged behind that of 
antibacterial agents. This is due to the cellular structure of the organisms 
involved. Bacteria are prokaryotic and hence offer multiple structural and 
metabolic targets which are different from those of the human host. But 
fungi are eukaryotes, and consequently most agents that are toxic to fungi 
are also toxic to the host. Furthermore, because growth of the fungi is slow 
and often exhibit various cellular forms, they are more difficult to quantify 
than bacteria. This difficulty complicates experiments aimed to evaluate 
the in vitro or in vivo properties of a potential antifungal agent. 
Major developments in the research of the azole  antifungal agents 
during the 1990s gave expanded options for the treatment of many 
opportunistic and systemic fungal infections. Fluconazole and itraconazole 
have proved to be safer than both ketoconazole and amphotericin B. Inspite 
of these advances, systemic fungal infections remain difficult to treat, and 
drug  resistance to the available drugs is upcoming. Use of the newer azole 
group of drugs  in combination with other antifungal agents with different 
mechanisms of action is likely to provide enhanced efficacy. Second-
generation  triazoles developed to provide extended coverage of  
opportunistic and emerging fungal organisms, as well as to overcome 
resistance to older drugs. 
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Classification of antifungals: 
Polyenes: 
1. Nystatin 
2. Amphotericin B 
Azoles 
1. Imidazoles 
 Clotrimazole 
 Ketoconazole 
 Miconazole 
 oxiconazole 
2. Triazoles 
 Fluconazole 
 Itraconazole 
 Voriconazole 
3. Allylamines 
 Naftifine 
 Terbinafine 
4. Benzylamines :  Butenafine 
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5. Echinocandins: 
 Capsofungin 
 Micafungin 
 Anidulafungin 
6. Hydroxypyridone: Ciclosporin  
7. Heterocyclic benzofurans:  Griseofulvin 
Polyene Antifungal Drugs 
Nystatin, amphotericin, and pimaricin (Natamycin)  belongs to this 
group. They  interact with sterols in the fungal cell membrane to induce 
osmotic instability. Ergosterol in fungi and cholesterol in humans  form 
channels through which small molecules leak from the inside of the fungal 
cell to the outside. 
Amphotericin B: 
It is derived from bacteria Streptomyces nodosus.it has broad 
spectrum of action against Candida and other deep fungal infections.it is 
fungicidal at high serum concentrations. It  is not absorbed orally. It has poor 
CSF penetration.It is metabolised in the liver and excreted through both 
urine and bile. It enhances the antifungal action of Flucytosine.  
The adverse effects are very high which include 
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• Acute reaction following each infusion which is characterised by 
fever, chills, nausea, vomiting, myalgia and dyspnoea lasting for 2-5 
hours injection of Hydrocortisone 0.6 mg/kg with the infusion may 
reduce the intensity of reaction 
• Nephrotoxicity  
• Bone marrow suppression and anemia 
• CNS toxicity 
Azole Antifungal Drugs 
Ketoconazole ,  fluconazole, and itraconazole belongs to this group. 
They   inhibit cytochrome P450-dependent lanosterol 14α-demethylase 
involved in the biosynthesis of ergosterol, which is necessary for the 
integrity of the cell membrane structure and function of fungus. Inhibition of 
this enzyme causes abnormal sterol accumulation inside the cell and leads to 
fungal cell death.  
Allylamine and Morpholine Antifungal Drugs 
Allylamines inhibit ergosterol biosynthesis at the level of squalene 
epoxidase. Terbinafine  and naftifine  are included in this group. Amorolfin, 
the morpholine drug, inhibits the same pathway at a later step. 
Echinocandins and cyclo peptides: 
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They are the newly discovered class of fungicidal agents.  They 
noncompetetively  inhibit the fungal cell wall β-D-glucan  synthesis via 
inhibition of the enzyme 1,3-β glucan synthase.  Examples of  echinocandins  
include  anidulafungin, caspofungin and micafungin.  Adverse events are 
fever, nausea, vomiting  and  infused-vein complications. They  are  less 
toxic drug. This drug causes embryotoxicity  hence  contraindicated in 
pregnancy. It  can be used in azole resistant Candida infection. 
Antimetabolite Antifungal Drugs 
 5-Fluorocytosine  acts as an inhibitor of both DNA and RNA synthesis 
via the intracytoplasmic conversion of 5-fluorocytosine to 5-fluorouracil. 
Fluorocytosine is available in the tablet form. 
 Side effects: 
• Nausea, vomiting, diarrhea, GI bleeding  
• Renal dysfunction 
• Hepatitis 
• Thrombocytopenia, anemia, and leukopenia. 
 At the manufacturer level, maintaining flucytosine levels from 25 to 
100 µg/mL is recommended. Laboratory monitoring including complete 
blood count, renal function test and liver function tests is mandatory. 
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Drug interactions: 
Azole antifungals are metabolized by cytochrome P450 enzymes and 
have considerable interactions with the other drugs metabolized by this 
enzymes. Metabolism of fluconazole is fastened by enzyme inducers like 
rifampicin and anti epileptics. Fluconazole has low propensity  to cause 
interaction. But  other azoles like ketoconazole, itraconazole  and 
voriconazole are contraindicated with  terfenadine, astimizole,cisapride as it 
produces ventricular  arrhythmias. These  drugs also increase the blood 
levels of sulfonylurea, statins, ergot alkaloidsprotease inhibitors especially 
ritonavir when given in the full dose(400mg) 
AZOLES: 
Structure : 
An  azole  is a class of five membered  nitrogen  heterocyclic  
ring compounds containing at least one other non-carbon atom of either 
nitrogen, sulfur, or oxygen. The basic compounds are aromatic and have 
two double bonds. There are successively reduced analogs called azolines 
and azolidines with fewer. Only one, lone pair of electrons from 
each heteroatom in the ring makes the aromatic bonding in an azole. Names 
of azoles maintain the prefix upon reduction (e.g., pyrazoline, pyrazolidine). 
The numbering of ring atoms in azoles starts with the heteroatom that is not 
part of a double bond, and then proceeds towards the other heteroatom. 
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Classification of azoles: 
The azole antifungals include two classes, imidazoles and triazoles, 
which share the same mechanism of action and antifungal spectrum . The 
systemic triazoles are metabolized very slowly and have less effect on 
human sterol synthesis than the imidazoles. Because of these advantages, 
new drugs under development are mostly triazoles. Of the drugs now on the 
market, ketoconazole, clotrimazole,  miconazole, econazole, oxiconazole, 
sertaconazole, butoconazole and sulconazole are imidazoles. Fluconazole, 
terconazole, itraconazole, , voriconazole, posaconazole, and isavuconazole 
which is an experimental drug  are triazoles.  Ketoconazole and miconazole 
have more effect on mammalian cytochromes than  triazoles  and tend to 
have severe adverse effects. Hepatotoxicity is common to all of them, and 
the risk of endocrine dysfunctions also exists, 
Mechanism of action 
At concentrations achieved after systemic administration, the major 
effect of imidazoles and triazoles on fungi is inhibition of a microsomal 
enzyme 14- alpha-sterol demethylase.  Imidazoles and  triazoles  impair the 
biosynthesis of ergosterol for the  cytoplasmic membrane and lead to the 
accumulation of 14-alpha-methylsterols. These intermediate metabolic 
products may disrupt the close packing of acyl chains of phospholipids and 
impair the functions of certain membrane-bound enzyme systems, thus 
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inhibiting growth of the fungi. Some azoles directly increase permeability of 
the fungal cytoplasmic membrane, but the concentrations required are only 
obtained with topical use. 
Ketoconazole: 
It is the first orally available imidazole. It is well absorbed orally. The 
absorption is pH dependent and variable with food.It reaches its peak plasma 
concentration at 1-2 hours of single dose.The drug does not penetrate CSF. 
So it is not used in fungal meningitis.It is metabolized in the  liver by the 
enzyme cytochrome 3A4. It is excreted in urine and feces. 
Adverse drug reactions: 
Hepatotoxicity is dreadful complication especially in patients with 
previous liver disease. Others are nausea, vomiting, abdominal pain, head 
ache,  giddiness, pruritus, gynecomastia, impotence ,loss of libido and 
oligospermia due to blockade of androgen synthesis by displacing 
testosterone from binding sites. Females get irregular cycles because the 
drug suppresses estradiol synthesis. It blocks the cortisol response to ACTH 
leading to adrenal insufficiency. It  is contraindicated in pregnancy 
(categoryC) 
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Interactions: 
• If coadministered with H2 blockers, Proton pump inhibitors and 
antacids,  oral absorption of ketoconazole is reduced because of 
lowered gastric acidity. 
• Rifampicin, INH and phenytoin decrease the efficacy of ketoconazole 
as they are cytochrome enzyme inducers.  
• Ketoconazole is the Potent cytochrome enzyme inhibitor thereby 
increasing the level of cyclosporin, statins. 
• With Terfenadine, astemizole and cisapride it causes ventricular 
tachycardia.  
Fluconazole: 
• Triazole  are fungistatic. The imidazole group is substituted by 
nitrogen group which shows improved antifungal activity and 
resistance to metabolic degradation. Mechanism of action is inhibition 
14α demethylase in fungal cell wall. It is supplied in IV, oral route, 
and eyedrops (0.3%) is also available. It has extensive absorption of 
>90% which is not gastric Ph dependent. The t1/2 is 25 to 30 hrs. 
Hepatic metabolism is less and  80% of the drug is excreted 
unchanged in urine. As the drug crosses blood brain barrier, it is 
useful for the treatment of fungal meningitis. 
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Adverse reactions: 
• Gastro intestinal symptoms like nausea, abdominal pain pain, 
diarrhoea  
• Torsades de pointes with/without concomitant drugs like cisapride and 
terfenadine 
• Hepatotoxicity  
• Rarely Steven Johnsons syndrome,toxic epidermal necrolysis 
• Pregnancy category  C  
Drug Interactions: 
• It is a Cytochrome P450, Cytochrome 2C9 Inhibitor in dose dependent 
manner. So influence the efficacy of the drugs metabolized by this 
enzymes. 
• It  precipitates arrhythmias if co administered with  Cisapride, 
terfenadine 
• Caution to be taken in patients having hypersensitivity to azoles, 
proarrhythmic cardiac conditions,renal impairment,Pregnancy and 
lactation  
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Itraconzole: 
• It is a broad spectrum fungistatic. It  is also a 14α demethylase  
inhibitor 
• It inhibits cyclic oxidase and peroxidative enzymes leads to increased 
peroxide generation and degradation of fungus at sub cellular levels. 
• Direct membrane damage by acting on membrane phospholipids  
• Food and gastric acidity enhances the absorption. So  the absorption is 
decreased in HIV patients due to gastric hypochlorhydria. 
• Hydroxypropyl beta cyclodextrin oral solution form exhibits better 
absorption in empty stomach  and in alkaline gastric ph. 
• It undergoes hepatic metabolism via cytochrome3A4 and excreted in 
feces and urine[30%]. In children less than 5 years, the drug attains 
low serum levels, so twice daily dosing is needed. The drug after 
intake is distributed to skin and its appendages like nail& nail bed, 
sebaceous and sweat glands. It is measurable in stratum corneum 3-4 
wks after discontinuation of drug. It donot penetrate CSF. The drug is 
indicated in candidial infection involving skin, mucosa,nail as well as 
deep mycosis.  
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Contraindications: 
• Hypersensitivity reactions 
• Along with cisapride, midazolam, pimozide, quinidine, doefitillide  
Use with caution : 
• Hepatic disease 
• Renal  disease, 
• COPD  
• Cardiac diseases[CCF,IHD,valvular HD-negative inotrpic effect] 
Voriconazole:  
• It is 2
nd
 generation broad spectrum triazole active against severe 
fungal infections Oral candidiasis ,Chronic muco cutaneous 
candidiasis, resistant candida and fusarium infections 
Adverse drug reactions: 
• SJS,TEN, Erythema Multiforme 
• Pseudoporphyria  
• Discoid Lupus Erythematosus 
• Photosensitivity reaction  
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Clotrimazole 
It is available as 1-2% cream, lotion lozenges, troches, powder, spray 
and solution. It causes leakage of intra cellular proteins, break down of 
nucleic acid, potassium efflux and finally cell death. 
Adverse drug reactions: 
• Rashes, itching, stinging sensation and burning  
• Irritant and allergic contact dermatitis especially to the ingredients and 
preservatives 
• Urticarial rashes  
Nystatin 
It is a  polyene  antifungal  derived from a bacteria, Streptomyces 
noursei. Currently, no injectable formulations of this drug is available 
because of its toxicity when the blood levels are elevated. The  biosynthesis 
of the  the compound involves enzymes like GDP-mannose dehydratase 
(nysIII), P450 monooxygenase (nysL and nysN), aminotransferase (nysDII), 
and glycosyltransferase (nysDI). 
Structure : 
Nystatin A1 (or referred to as nystatin) is biosynthesized by a bacterial 
strain, Streptomyces noursei. The structure of this active compound is 
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characterized as a polyene macrolide with a deoxysugar D-mycosamine, an 
amino glycoside.The genomic sequence of nystatin reveals the presence of 
the polyketide loading module and two thioesterase. Thus, it is evident that 
the biosynthesis of the macrolide functionality follows the polyketide 
synthase I pathway 
Mechanism of action: 
Like amphotericin B and natamycin, nystatin binds to ergosterol, which is a 
major component of the fungal cell membrane. When present 
• With sufficient concentrations, it forms pores in the membrane that 
lead to K
+
 leakage, acidification, and death of the fungus. 
•  Ergosterol, is unique to fungi, so the drug does not have such 
catastrophic effects on animals or plants. However, many of the 
systemic toxic effects of Nystatin are attributable to its effect on 
human cells via binding to mammalian sterols, namely cholesterol.  
• This is the effect that accounts for the nephrotoxicity observed 
when high serum levels of Nystatin are achieved. 
Uses: 
Candidiasis  involving  skin, vaginal mucosa  and  esophagus  usually 
respond well to treatment with nystatin. It  is available in many forms. Oral 
nystatin tablets is often used as a preventative treatment in risky individuals 
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for fungal infections, such as HIV positive individuals with a low 
CD4
+
 count and patients receiving immunosuppressive drugs. 
It is also used  in Very Low Birth Weight (<1500 g) infants as 
prophylaxis to prevent invasive fungal infections, though fluconazole is the 
preferred agent. The drug also reduce mortality when used in such babies. 
Current  clinical  guidelines states that the use of these agents should be 
restricted to  extremely low  birthweight   infants (<1000g) in NICU with  
fungal infection. 
Investigational  use of  Liposomal Nystatin has shown greater in 
vitro activity than colloidal formulations of Amphotericin B, and found 
effective against some Amphotericin B resistant  fungal infections. It is also 
used to treat  systemic infections, such as invasive  aspergillosis.  Liposomal   
Nystatin appears to cause less chance of severe nephrotoxicity than observed 
with Amphotericin B. 
Formulations : 
• An oral suspension form is used for the prophylaxis or treatment of 
oropharyngeal thrush .A tablet form is preferred for candidal infections of 
GIT 
• It is also available as a topical cream and can be used for superficial 
candidal skin infections. 
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•  A liposomal formulation of nystatin was investigated in the 1980s and 
into the early 21st century  and was intended to resolve problems arising 
from the poor solubility of the parent molecule and the associated 
systemic toxicity of the free drug. 
Adverse effects: 
The oral suspension  produces a number of adverse effects including 
• Abdominal pain 
• diarrhoea 
• Rarely, tachycardia, facial swelling, bronchospasm and myalgia Both 
the oral suspension and the topical form can cause: 
1. Hypersensitivity like Stevens-Johnson syndrome in few cases 
2. Rash, burning sensation are common with topical forms 
Spectrum of Antifungal action: 
Azoles as a group have clinically useful activity against Candida 
albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, 
Cryptococcus neoformans, Blastomyces dermatitidis, Histoplasma 
capsulatum, Coccidioides spp., Paracoccidioides brasiliensis, and ringworm 
fungi (dermatophytes). Aspergillus spp., Scedosporium apiospermum 
(Pseudallescheria boydii), Fusarium, and Sporothrix schenckii are 
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intermediate in susceptibility. Candida krusei and the agents of 
mucormycosis are more resistant. Posaconazole has slightly improved 
activity in vitro against the agents of mucormycosis. 
Resistance: 
Widespread use of azoles resistance has lead to the emergence of both 
primary and secondary resistance, causing clinical failure with advanced 
HIV infection and esophageal or oropharyngeal candidiasis. The main 
mechanism of resistance in Candida albicans is the  accumulation of 
mutations in ERG11, the gene which codes for the 14-alpha-sterol 
demethylase. The above mutations protect heme in the enzyme pocket from 
binding to the azole but allow access of the natural substrate for the enzyme 
lanosterol. 
Cross-resistance is seen in all azoles. The azole efflux by both ATP-
binding cassette (ABC) and major facilitator transporters can enhance 
fluconazole resistance in Candida albicans and Candida glabrata. Excess  
production of C14-alpha-sterol demethylase is another potential factor of 
resistance. C5,6 sterol reductase gene ERG3 mutation also can increase azole 
resistance in some species. 
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Antifungal susceptibility: 
It is designed to provide information that helps the treating physician 
to select the appropriate antifungal agents. Isolates of same species may 
exhibit differences in MIC because of previous exposure to antifungals or 
genetic mutations. AmphotericinB, 5fluorocytosine, ketoconazole, 
itraconazole, voriconazole  and  fluconazole are common antifungals that are 
tested. Now  newer antifungals are added to this list. National committee for 
clinical laboratory standards(NCCLS) has defined a standard for antifungal 
sensitivity testing. But its use in the clinical aspects are very limited because 
all azole resistant candidiasis cannot be explained by invitro methods. 
Resistance is more common with non Candida albicans species. Increasing 
the dosage of currently using drug, changing new drug, using combination of 
drugs are the alternate option for the above problem. 
Two most common methods are used for susceptibility. 
 Micro dilution method 
 Disc diffusion method 
Treatment regimens  of VVC: 
The cell wall of Candida is a complex glycoprotein that depends on 
the biosynthesis of ergosterol. Azole compounds, found in antimycotic 
drugs, are believed to block ergosterol production, allowing topical 
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antimycotics to achieve cure rates in excess of 80%. The only oral azole 
agent approved for this indication by the US Food and Drug Administration 
(FDA) is fluconazole, which also shows a high cure rate. Adequate 
therapeutic concentrations are found in vaginal secretions for 72 hours after 
the ingestion of a single 150-mg tablet. 
In considering treatment, distinguishing between sporadic and 
recurrent episodes of vulvovaginal candidiasis  is of great importance. 
Uncomplicated sporadic VVC is caused by C.albicans. These strains exhibit 
sensitivity to   azole antifungals. 
Studies have shown there is no marked difference in the clinical 
efficacy of various topical  azole antifungals. So starting empirical treatment 
without waiting for culture results is advisable. In uncomplicated cases 
treatment is selected according to patient’s preferences. 
Ample number of antifungal  regimens are available for the treatment 
of vulvovaginal candidiasis including oral and topical agents. But  drug 
interaction with oral usage must be taken in to consideration. Hepatotoxicity 
secondary to ketoconazole therapy occurs in approximately 1 in every 
10,000-15,000 individuals exposed to this drug. Side effects  include nausea, 
abdominal pain, and headaches can also occur. Drug interactions  occur with 
simultaneous use of warfarin ,calcium channel antagonists, theophylline, 
rifampicin,  cyclosporine, oral hypoglycemic agents, protease inhibitors and 
to name a few.  
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In comparative trials of 10-14 of course of therapy azoles scored 
higher clinical cure rate (80 -95%) than another effective topical agent, 
nystatin (70-80%). Azoles found to be more efficacious even if given for less 
than 14 days. 
CDC – guide lines 2010 
1. Clotrimazole 1% cream 5g intra vaginally daily for 3 days 
Clotrimazole  100 mg vaginal tablet daily for 3 days 
2. Butoconazole 2% cream 5g intravaginally daily for 3 days 
3. Miconazole 2% cream 5g intravaginally for 7days(or) 
Miconazole 1200 mg vaginal supporitony -10 D× 1 day (Or) 
Miconazole 200mg vaginal supporitory Od for 3 days (or) 
Miconazole 100 mg vaginal supporitory 1 od for 7 days 
4. Tioconazole 6.5% ointment 5g intravaginally in a simple application 
5. Butoconazole 2 % cream-  single dose,  bioadhesive product 5g 
gingivally for 1 day. 
6. Nystatin 1,00,000 unit vaginal tablet 10 D for 14 days (or) 
7. 0.4 %Terconazole  cream 5 g intravaginally for 7 days (or) 
0.8 %Terconazole  cream 5 g intravaginally for 3 days (or) 
Terconazole 80mg vaginal supporitory for 3 days 
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Oral Agents 
T. Fluconazole 150 mg  single dose. 
WHO guidelines(2003) 
1. Miconazole (or) clotrimazole 200 mg pessary intravaginal daily for 3 
days (or) 
2. Clotrimazole 500 mg pessary intravaginally in a single dose or 
3. T.Fluconazole 150 mg orally as a single dose 
Alternative regimen 
Nystatin 100000 unit vaginal tablet OD for 14 days 
Other Regimens: 
• Clotrimazole 500 mg intravaginally single application 
• Clotrimazole 200 mg intravaginally for 3 days 
• Tioconazole 2% cream 5 gm  intravaginally for 7 days 
For recurrent VVC 
Several  studies have  shown  that  antifungal  maintenance  suppressive  
therapy for several months is effective in RVVC. 
Some  regimens includes: 
1. Tab .ketoconazole 400 mg per week 
2. Tab. Itraconazole 50-100 mg per week or 400mg monthly  
3. Tab .Fluconazole 100 mg per week  
4. Clotrimazole 500 mg vaginal suppositories once per week 
The above regimens are used upto six months. 
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The cure rates for vulvovaginal candidiasis  is72% to 98% in most of 
the studies done on patients without HIV infection. Previously, the standard 
regimen  for vulvovaginal candidiasis typically consisted of topical forms of 
clotrimazole or miconazole for 7 days. However, shorter courses are  proved 
to be equally effective. Response  to topical treatment for 3 days is 
equivalent to topical therapy for 7 days. In a study comparing a single dose 
of fluconazole 150 mg orally  vs 7 days of  topical clotrimazole therapy  
with100-mg vaginal suppositories, the clinical cure rate (75%) in the 2 
groups was equivalent by day 35.  Mycologic eradication rates were 63% for 
the fluconazole group at day 35 and  for the clotrimazole group it was 57%. 
Either topical or systemic therapy is effective in women with HIV infection, 
but relapse rates may be quite more. 
 Most of the Candida infections respond to empiric antifungal therapy. 
The reliability of  invitro testing for antifungal resistance is less when 
comparing to antibiotic susceptibility testing of bacterial isolates. 
Non albicans VVC 
   It  includes longer duration of therapy (7–14 days) with preferably a 
nonfluconazole azole drug either oral or topical as first-line therapy. In  
case of recurrence , 600 mg of boric acid in gelatin capsule form is 
advised. It  has to be administered intravaginally once daily for 2 weeks. 
This regimen has shown 70% clinical and mycologic eradication rates.  
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Topical boric acid has been used for long time as a treatment for 
vulvovaginal candidiasis.  Though  it is effective against non candida 
albicans infection, it is categorised as a poison and may be absorbed  
through the vaginal mucosa and reaches significant serum levels.
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protection, it is encapsulated in a gelatinous capsule and administered as a 
suppository. Treatment includes 600 mg in size 0 gelatin capsules 
administered intravaginally every day for 2 weeks. 
Preventive measures of Complicated VVC: 
• As   ingested sucrose and lactose may support and promote the 
growth of yeast, the patients should  limit their dietary intake of 
such sugars . 
•  Patients are also advised to wear loose-fitting, nonocclusive 
clothing and cotton underwear to avoid providing the warm, moist 
climate in which Candida tends to thrive.  
• Some  recommend using panty liners and washing clothing in hot 
water  to avoid creating a reservoir for the fungus  
• Adequate glycemic control should be maintained  in diabetic 
patients. 
•  Cessation of OCP’s results in reduction in the frequency of clinical 
episodes. 
•  Repeated unnecessary antibiotic intake should be avoided. 
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Sober’s multi center prospective randomized study on maintenance of 
Fluconazole therapy in RVVC in 387 women , half  were put on placebo and 
other  half  put on Fluconazole 150 mg induction, followed by 150 mg pulses 
weekly. After six months 98.5% were disease free; at nine months 73.2%, at 
12months 42.9% were disease free.
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Observation and results 
 A total of 80 symptomatic female patients above 18 years who 
fulfilled the inclusion criteria  were screened. Diagnosis of vulvovaginal 
candidiasis  was confirmed in 50 case and they were taken for culture and 
sensitivity testing. The results we obtained is analysed and summarised in 
this section. All the results obtained were analysed statistically for their 
completedness, consistency and accuracy. 
TABLE 1:  
Age wise distribution of VVC 
 
Age  
 
   
  Number of patients 
 
    Percentage  
 
         18 – 35 years 
 
   
            44 
       
      55% 
         
        36 -50 years 
 
 
   
            31 
 
     38.7%  
         
        >50 years 
 
 
    
             5 
       
      6.3% 
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The 80 study subjects  were analysed based on age and tabulated( 
table1). Of the 80 patients , 44(55%)  belonged  to18-35 years; 31 patients 
(38.7%) belonged  to the age group of  36 – 50 years and only 5 patients 
(6.3%)  were in the  age group of 50  and  above. So majority of the patients 
fall in the reproductive  age  group (18-35years)  were vulnerable to get 
VVC. 
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TABLE - 2 
Analysis of clinical pattern of VVC 
CLINICAL 
FEATURES 
NO. OF 
PATIENTS 
HIV STATUS SPECIES 
 
Positive  
 
Negative 
C. 
Albicans 
Non C. 
Albicans 
Asymptomatic 
cases 
2 1 1   
Itching of vulva 
 
78 38 40   
Scanty  
discharge 
 
19 6 13  1 
Profuse curdy 
white precipitate 
51 29 25 43 8 
Soddening of 
vulva 
 
2 2    
Maceration of  
vulva,adjacent 
sites 
8 2 6 6 2 
Satellite 
pustules 
 
1 1    
Erosion 
,inflammed 
fissuring 
6 1 5 3 3 
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All the study group patients were symptomatic except  2 patients. 19 
patients had scanty vaginal discharge. Among this,13 were HIV negative.  51 
patients had  presented with profuse vaginal curdy white discharge  amongst  
which 29  patients were HIV positives and 25 were HIV negative. 2 HIV 
positive patients showed soddening. Maceration of vulva and adjacent skin 
was seen in 8 patients and 6 of them were HIV negatives. Erosions, glazened 
appearance and fissuring was seen in 6 patients, five of them were HIV 
negative patients. Satellits pustules over the groins was seen in  one patient 
only. 
 Among non Candida albicans species,all  had itching and profuse 
vaginal discharge. Six patients had  erosions, maceration and glazened 
appearance of the adjacent skin. 
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TABLE:3 
Comparison of VVC and associated vaginal infections 
Associated 
infections 
Number of 
patients 
Percentage 
 
Bacterial 
vaginosis 
5 6.25% 
 
Trichomonas 
vaginalis 
4 5% 
 
Herpes genitalis 
3 3.75% 
 
Genital warts 
1 1.25% 
 
No association 
22 27.5% 
 
 Among the 80 study subjects, 5 patients  were  coinfected  with 
bacterial vaginosis(6.25%); 4 patients were coinfected with Trichomonas 
vaginalis(5%). Coexistent herpes genitalis was  seen in 3 patients (3.75%). 
Genital warts  were seen in only one patient(1.25%). The remaining 22 
patients  were not associated with any other infections.  
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TABLE :4 
Analysis of predisposing factors for VVC: 
Precipitating factors Number of 
patients 
Percentage  
 
Antibiotics usage 
8 10% 
 
Intrauterine devices 
2 2.5% 
  
Immunosuppressive 
drugs 
2 2.5% 
 
Diabetes mellitus 
6 7.5% 
 
HIV 
39 48.7% 
 
 Of the 80 women,8 patients (10%)  had  H/O antibiotics usage in the 
recent past for some respiratory illness. Two patients (2.5%) presented with 
IUCD in situ, another 2 patients(2.5%) were on immunosuppressive drugs; 6 
patients (7.5%)  were diabetic not under glycemic control  and 39 out of 80 
were HIV positive(48.7%). 
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TABLE:5 
Analysis  of relationship between  RVVC  and  HIV positivity 
HIV status 
 
 
Number of patients Percentage 
Positive 
 
 
6 60% 
Negative 
 
 
4 40% 
 
We have identified 10 cases of RVVC in the study group. Among the 
10 cases, 6(60%) are HIV positive and 4 cases (40%) are HIV negative. 
Among the HIV negatives, 2 cases are diabetics and 2 cases are normal 
subjects. Their CD4 counts were in the range of 150 to 400 cells/µL. 
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TABLE: 6 
 
Identifying species prevalence in the study group 
 
Species 
  
Number of patients Percentage  
 
Candida albicans 
 
41 82% 
 
Candida glabrata 
 
4 8% 
 
Candida krusei 
 
2 4% 
 
Candida tropicalis 
 
3 6% 
 
Among 80 patients, 50 are confirmed cases of  VVC by culture in 
SDA agar and Chrome agar. Among the culture positive  cases ,41cases 
(82%) are Candida albicans; 4 cases (8%) are C.glabrata; 2 cases (4%)  are 
C.krusei and 3 cases (6%) are C.tropicalis. 
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TABLE :7 
Analysis of drug sensitivity pattern in VVC 
Drugs 
  
Sensitive Percentage Resistant  Percentage  
Fluconazole 
 
41 82% 8 16% 
Itraconazole 
 
40 80% 8 16% 
Nystatin  
 
45 90% 3 6% 
Clotrimazole 
 
37 74% 6 12% 
Voriconazole 
 
28 56% 15 30% 
Miconazole  
 
26 52% 13 26% 
Ketoconazole 
 
20 40% 23 46% 
 
Of the 50 culture positive cases, the isolates  were subjected to drug 
sensitivity by disc diffusion method.45 cases (90%) were sensitive to 
nystatin; 41 cases(82%) are sensitive to fluconazole;40 cases(80%) were 
sensitive to itrconazole;37 cases(74%)  were sensitive to clotrimazole other 
drugs like ketoconazole, miconazole, voriconazole  were less sensitive. 
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TABLE: 8 
Analysis of drug sensitivity pattern in Candida albicans 
Drugs 
  
Sensitive  Percentage  Resistance  Percentage  
Fluconazole 
  
34 82% 7 18% 
Itraconazole 
  
35 85.3% 6 14.7% 
Nystatin  
 
36 87.8% 5 12.2% 
Clotrimazole 
  
31 75% 10 25% 
Voriconazole  
 
31 75% 10 25% 
Ketoconazole  
 
16 39% 25 61% 
Miconazole  
 
22 53% 19 47% 
 
Among the 41 proved cases of  Candida albicans, Fluconazole, Itraconazole, 
Nystatin  were highly sensitive drugs (more than 80 %). 36 cases were 
sensitive to nystatin; Itraconazole  was sensitive  in 35 patients; Fluconazole  
was sensitive in 34 patients(82%)  and  voriconazole  was sensitive in 
31(75%) patients. Others like clotrimazole, ketoconazole, miconazole  were  
sensitive in 31(75%),16(39%), 22(53%)  patients respectively. 
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TABLE - 9 
Drug sensitivity pattern in non Candida albicans  patients 
Drugs  
 
Sensitivity  
(No of 
patients) 
Percentage  Resistance 
(No of 
patients)  
Percentage 
 
Fluconazole 
 
7 
 
77.7% 
 
2 
 
22.3% 
 
Itraconazole 
 
6 
 
66.6% 
 
3 
 
33.3% 
 
Nystatin 
 
9 
 
100% 
 
0 
 
0 
 
Clotrimazole 
 
7 
 
77.7% 
 
2 
 
22.3% 
 
Voriconazole 
 
7 
 
77.7% 
 
2 
 
22.3% 
 
Ketoconazole 
 
5 
 
55.5% 
 
4 
 
44.5% 
 
Miconazole 
 
7 
 
77.7% 
 
2 
 
22.3% 
 
Among  the 9  nonCandida albicans group all were sensitive to 
nystatin(100%). Fluconazole , clotrimazole, voriconazole and miconazole 
showed  sensistivity  in 7 (77.7%) patients. Six patients (66.7%) were 
sensitive to itraconazole. Ketoconazole was least sensitive (55%). 
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CHART - 8 
Analysis of sensitivity pattern in non candida albicans group: 
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TABLE 9(A): 
C. glabrata 
Drugs Sensitive Resistance 
 
Fluconazole 
3 1 
 
Itraconazole  
2 2 
 
Nystatin 
4 0 
 
Clotrimazole 
2 2 
 
Voriconazole 
3 1 
 
Ketoconazole 
3 1 
 
Miconazole  
3 1 
 
Among 4 cases of candida glabrata , 3cases  showed  sensitivity to 
fluconazole ,voriconazole ,miconazole and  one case  was  resistant to 
fluconazole. Itraconazole  was  sensitive in 2 cases and resistant in 2 cases. 
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TABLE 9(B) 
Drug sensitivity in Candida tropicalis 
 
Drugs  
Sensitive  Resistance  
 
Fluconazole 
3 0 
 
Itraconazole  
3 0 
 
Nystatin 
3 0 
 
Clotrimazole 
3 0 
 
Voriconazole 
3 0 
 
Ketoconazole 
2 1 
 
Miconazole  
2 1 
 
All the 3 cases of candida tropicalis  were sensitive to fluconazole, 
itraconazole and nystatin. One case  was  resistant to clotrimazole and 
miconazole.  
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TABLE :9 (C) 
Drug sensitivity in Candida krusei: 
 
Drugs  
Sensitive  Resistance  
 
Fluconazole 
1 1 
 
Itraconazole  
1 1 
 
Nystatin 
2 0 
 
Clotrimazole 
2 0 
 
Voriconazole 
1 1 
 
Ketoconazole 
0 2 
 
Miconazole  
2 0 
 
One out of two cases  was  sensitive to Fluconazole ,Itraconazole , 
Voriconazole and  one  case  was resistant  to the above drugs. Both 2 cases 
showed  sensitivity to nystatin ,clotrimazole, ketoconazole and both 2  were 
resistant to miconazole. 
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TABLE 10: 
Prevalence of candida and non candida species in HIV positive patients 
SPECIES 
HIV 
POSITIVE 
PERCENTAGE 
HIV 
NEGATIVE 
PERCENTAGE 
C.albicans 22 53.6% 19 46.4% 
Non 
C.albicans 
 
3 
 
33.3% 
 
6 
 
66.7% 
 
Of the total 41cases of Candida albicans , 22 {56.4%} were  HIV 
positive and 19(48.7%)  were HIV negative. Among  the 9 non  candida 
albicans  group, 3 cases (33.3%) were HIV positive and 6(66.7%)  were HIV 
negative. 
 
 
 
 
 
 
 
94 
 
CHART -9 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
C.albicans Non C.albicans
Candida and non Candida species in HIV positives
HIV POSITIVE
HIV NEGATIVE
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure:1 - Curdy White Patches of Discharge in the inner aspect 
of labia minora & Fourchette 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 2 - Thick Curdy White discharge with inflammed vaginal 
mucosa in speculam examination 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 3 – Maceration and Erosion involving Vulva and 
adjacent skin. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 4 – Soddening of Vulva and Intertrigenous Area 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 5 – Vulvo Vaginal Candidiasis with Mutiple Genital warts 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 4 – Large Herpetic Ulcer with secondary Candidiasis in 
the Anogenital Region. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure :7 – KOH Mount of Vaginal Smear with Branched Hyphae & yeasts 
 
 
 
 
 
 
 
 
 
 
 
 
Figure :8 – Sabourauds Dextrose Agar with smooth  Creamy dome shaped 
colonies of Candida Albicans 
  
 
 
 
 
 
 
 
 
 
 
 
Figure : 9 – HI chrome Agar Media showing smooth Green Coloured wet 
colonies of Candida Albicans 
 
  
 
 
 
 
 
 
 
 
 
 
Figure : 10- HI chrome Agar Media showing pink coloured wet colonies of 
candida glabrata 
  
 
 
 
 
 
 
 
 
 
 
Figure : 11- HI chrome Agar Media showing Metallic Blue Coloured 
Colonies of Candida Tropicalis 
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Figure : 12 - HI chrome Agar Media showing white to dull pink colour 
colonies of candida krusei 
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Figure : 14 - Drugs Sensitivity by disc diffusion method showing Multi 
Drug resistant Pattern  
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DISCUSSION 
Vaginal candidiasis is a common infection in 60 to 70% of females of 
child bearing age. This study was done among the people attending the STD 
clinic of Dermato-Venereo-Leprology department with complaints of 
vaginal pruritus and discharge revealed highest frequency of vaginal 
candidiasis in the age group of 18 to 35 years which constitutes 55% 
followed by 36-50 years of age group(38.7%) as depicted in chart 1.Least 
frequency of around 6.3% is observed in menopausal age group. The studies 
done by A.K. Ako-nai, O.O.Kasimet al,Deepa babin et al
55
 and Shegal et al
56
 
also showed the higher frequency of vulvovaginal candidiasis in the 
reproductive age group which was  similar to our observation. 
 We have analysed the clinical presentation of VVC and correlated 
with HIV status and recurrence. Among the study group 97% were 
symptomatic patients. All  had itching of the vulva and vagina. HIV negative 
and positive  patients  had more or less similar symptoms except for  scanty 
vaginal discharge in 13 HIV negatives versus  6 HIV positives. One HIV 
positive case with recurrent VVC had severe symptoms with maceration and 
satellite pustules in the adjacent areas. But severe forms of VVC was more 
common in HIV negative patients infected with non Candida albicans 
species. Among non Candida albicans group, 2/3
rd
 of the patients had 
profuse curdy white discharge with vaginal wall inflammation, erosions and 
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maceration of the adjacent areas. There is no much difference in  the clinical 
features between HIV positive and HIV negative women as observed in 
study done by Singh S, Sobel JD, Wiesenfield HC, Marten’s et al.
57 
 
 We have analysed the predisposing factors for vulvovaginal 
candidiasis and tabulated (table 4). In our study HIV is the major 
predisposing factor. Out  of  80 cases 39 were HIV positives. A study done 
by E.Shifrin et al
58
, Duerr et al, A.Spinillo et al
63,64 
 published that VVC was  
one of the most common opportunistic fungal infection in HIV positive 
women because of depressed cell mediated immunity.  Studies done by 
Ohmit SE, Schuman P et al also documented the same. 
Frequent and prolonged antibiotic usage in the recent past was a major 
factor and it constitutes 10% in the total study group. Studies done by 
Spinillo A et al, Capuzzo et al,
59
 Pirotta et al
60
 documented that high 
prevalence of symptomatic vulvovaginal candidiasis was seen in frequent 
and prolonged antibiotic use. We observed  the same finding in our study. 
 Co existing diabetes mellitus especially when uncontrolled has been 
the second most common risk factor in this study(7.5%). Similar 
observations were noted in studies done by De Leon et al
61 
 Dehemet elm et 
al, Jacober et al, Donderrs G
62
 et al showing diabetes was the frequent 
predisposing factor for vulvovaginal candidiasis  because hyperglycemia 
provides enrichment for the growth of the Candida in the vagina and also 
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resistant to antimycotics. In our study also 3 out of 6 diabetic patients(50%) 
are resistant to fluconazole and itraconazole. 
 We also correlated the IUCD and immunosuppressive drug intake in 
the causation of  vulvovaginal candidiasis. Both factors carries the same 
weightage (2%) in the causation of vulvovaginal  candidiasis. Barbone F’et 
al
65.
 described the IUCD usage was associated with increased risk of 
infection. Apart from IUCD, oral contraceptives, diaphragm and spermicide 
also predisposes to vulvovaginal candidiasis (Hooten et al)
66
. 
 We have analysed the  coinfections with vulvovaginal candidiasis in 
our study group . The  genital  coinfections  which occurred  in higher 
frequencies were  bacterial vaginosis (6.25%),  trichomonas vaginalis (5%), 
herpesgenitalis (3.75%) and genitalwarts (1.25%) in decreasing order of 
frequency. 22 women (27.5%) had no associated infections.  HIV is the most 
common association in vulvovaginal candidiasis.
67
 39 cases out of 80 cases 
are HIV positive and 9 out of 39 positive  cases had oral candidiasis .  
Oropharyngeal  and oesophageal candidiasis  showed increased frequency in 
HIV positive patients was observed in studies done by Fitchenbaem et al.
67
 Regarding  recurrent vulvovaginal candidiasis, we identified 10 cases 
out of which 6 cases were HIV positves and 4cases were HIV negative. 
Studies  on recurrent vulvovaginal candidiasis  done by Roads et al.
68
  
documented RVVC was common in HIV positive women and correlated the 
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impact on clinical and microbiological characteristics. He also stated that the 
incidence of RVVC correlate with advancing immunosuppression.  
We analysed the most prevalent species among the culture positive 
cases and observed that 82% were C.albicans and 18% were non candida 
albicans(Spinilo et al). We isolated 9 cases of non candida species, of which 
4 (8%) belongs to C.glabrata,3(6%) belongs to C.tropicalis, and 2 cases(4%) 
belongs to C.krusei. Reports from Uma et al,Deepa babin et al,Mahumodi et 
al,Fan et al,Paul nyiojery  et al
69
 have also  documented  similar results. In 
our study C.glabrata was most common followed by C.tropicalis and C 
krusei. The emphasize on non C.albicans was very essential because of drug 
resistance. Various study reports done by sobel et al,
69
 Spiniliio et al, 
Redondo et al
70
 were similar to our results. Hence  speciation by reliable 
culture methods is beneficial  in the diagnostic  aspect. 
In our study we correlated the prevalence of vulvovaginal candidiasis 
with HIV status of  the patients. Of the 50 culture positive cases 22 out of 
41cases of candida albicans were HIV positive(56.4%). Non  candida 
albicans in HIV positives are 33.3%which was less than the cases found in 
HIV negatives(66.7%).Studies done by sober et al,  Horowitz et al ,A 
Spinillo et al documented that non candida species were more prevalent in 
HIV positive patients. But our study results  found that non candida albicans 
were more prevalent in HIV negatives only. 
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In vitro drug sensitivity testing has been improved over the past few 
years because increased incidence of primary and acquired resistance to 
azoles. Some studies documented that the invitro resistance to antifungal 
medication  was common
71
. Although clinical and invitro drug resistance to 
candida albicans was uncommon, non candida albicans  were less likely to 
respond to azole antifungal therapy
72
.The rate of fluconazole resistance vary 
from  5-25%. But the rate of resistance was  high in ketoconazole and 
itraconazole (5-56%). Similar observations  were  noted in our study results  
revealed  highest  susceptibility to  nystatin (90%)  followed  by  fluconazole 
(82%), itraconazole (80%), voriconazole (75%) clotrimazole(75%).  
Ketoconazole and miconazole  were less sensitive. Regarding resistance  
pattern, ketoconazole (61%) was more resistant followed by  
miconazole(47%). 
We also compared the susceptibility of  C. albicans and non candida 
albicans drug sensitivity. For candida albicans, sensitivity to nystatin(87.8%) 
is high followed by  itraconazole (85.3%), fluconazole(82%) 
clotrimazole(75%)  and  voriconazole(75%). Ketoconazole showed high 
level resistance. 
Regarding noncandida albicans,3 out of 4(75%)  candida glabrata 
showed  sensitivity to fluconazole ,voriconazole ,miconazole and only 25% 
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was resistant to fluconazole. Itraconazole was sensitive in 2 cases(50%) and 
resistant in 2 cases(50%). 
Drug sensitivity in Candida tropicalis showed all the 3 cases (100%) 
to be sensitive to  fluconazole, itraconazole and nystatin and  one case was 
resistant to clotrimazole and miconazole. Drug sensitivity in candida krusei, 
2 cases  showed 100% sensitive to nystatin. Azoles(fluconazole, 
itraconazole, voriconazole)  were only 50% sensitive. Both the cases were 
resistant to miconazole. While comparing our results with other studies done 
on drug susceptibility pattern, all the three non C.albicans species showed 
highest sensitivity to nystatin.  
Out of 9 cases of non Candida albicans  all were sensitive to nystatin. 
66 to 78% sensitivity  was observed  to fluconazole, voriconazole, 
clotrimazole and itraconazole.  Ketoconazole  showed least sensitivity 
(55%).  Further analysis of drug sensitivity pattern in large study group  is 
necessary. Our study showed similarity with  a study  done by Panchal et 
al
73,74
 in western India. 
We  compared the drug  susceptibility pattern of Candida  albicans 
and  non Candida albicans  in this study which  showed  similar pattern of 
sensitivity and  resitance in both groups. Nystatin  scored the highest 
sensitivity followed by fluconazole, itraconazole and voriconazole.  
Ketoconazole  showed  highest resistance in both groups. 
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Summary 
The following are the implications derived from this prospective study 
on clinicomycological study of vulvovaginal candidiasis among the patients 
more than 18 years of age over a period of one and a half years. 
 The most common age group affected was 18 to 35 years which 
constitutes 55% of the study group 
 Clinical presentation of VVC was similar in HIV positive and HIV 
negative patients. Severe forms were found in non Candida albicans 
and RVVC patients.  
 The most common predisposing factor was HIV infection induced 
immunosuppression[48.7%] followed by antibiotic usage and diabetes 
mellitus. 
 The most common associated infection was HIV [48.7%] followed by 
bacterial vaginosis and trichomonas vaginalis. 
 Recurrent vulvovaginal candidiasis [RVVC]  makes up 12% of total 
cases. Two third  of them were HIV positives. 
 The most common species isolated was Candida albicans which 
constituted  82% and the rest  were non Candida albicans species. 
 Candida glabrata was the most prevalent species among the non 
Candida albicans. 
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 Drug sensitivity pattern  of  Candida albicans  showed  highest 
sensitivity to  Nystatin 85.7% followed by triazoles [75-85%]. 
Ketoconazole  was more  resistant[40-60%] 
 Drug sensitivity pattern of non candida albicans showed 100% 
sensitivity to nystatin followed by triazoles [66-77%]. Ketoconazole  
showed  highest resistance [45%]    
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Conclusion 
Vulvovaginal candidiasis  is common among  women in the 
reproductive age group. Among various predisposing factors the deficient 
immune status of HIV predispose to pathogenic colonisation of vagina and 
frequent recurrences. Besides HIV some other  factors  like  antibiotics, 
diabetes mellitus,  IUCD usage  and  immunosuppressive drug  intake  also 
predisposes  to vulvovaginal candidiasis. Species identification by culture 
methods showed Candida  albicans to be the most prevalent species 
including the HIV positive patients in this study. Emergence of  few 
nonCandida  albicans species, recurrent vulvovaginal candidiasis 
necessitates the species identification and antifungal susceptibility to be done 
as a part of laboratory evaluation of vaginal candidiasis. Fluconazole , 
itraconazole and  voriconazole  were sensitive in both  Candida albicans  and 
non Candida albicans  infections.  Nystatin was found to be  the highly 
sensitive drug followed by triazoles. Ketoconazole and miconazole were  
highly resistant to both Candida and non candida albicans species. 
According  to  our  study  results ,  elimination of predisposing factors  and  
ensuring  good immunity with identification of causative fungal species and 
treatment according to the drug sensitivity pattern will reduce the incidence 
of vulvovaginal Candidiasis. 
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ABBREVIATIONS IN MASTER CHART 
 
HIV  -  Human Immune Deficiency Virus 
BV      -  Bacterial Vaginosis 
TV  - Trichomonas Trichomonas Vaginalis 
W  -  Genital Warts 
HSV  - Herpes Genitalis 
OC  - Oral Candidiasis 
DM  -  Diabetes Mellitus 
PID  - Pelvic Inflammatory Disease 
AB  - Antibiotics 
IUCD  - Intra Uterine Contraceptive Devices 
IMDr  - Immunosuppressive Drug Intake 
VVC  - Vulvovaginal Candidiasis 
RVVC - Recurrent Vulvovaginal Candidiasis 
YES  -  Culture Positives 
CN  -  Culture Negatives 
S  - Sensitive 
R  - Resistant 
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1 Muthathal 60 + - + + + + - - Yes Yes S S S S S R R
2 Vadivoo 32 + + - - - - - - CN
3 Kamsala Devi 28 + + - - - - - - CN
4 Iyyammal 21 + - + - - - - - CN
5 Devi 32 + + - - - - - - CN
6 Selvi. N 40 + - + - - - - - HIV CN
7 Ramalakshmi 37 + - + - - - - - HIV BV CN
8 Ameena 46 + - + - - - - - CN
9 Mariammal. P 30 + - + - - - - - HIV CN
10 Subbulakshmi 32 + - + - - - - - HIV CN
11 Valarmathi 25 + - + - - - - - TV Yes Yes S S S S S R R
12 Mary 38 + - + - - - - - HIV Yes S S S S R R R
13 Vijila 33 + - + - - - - - Yes S S R S R R R
14 Muthuselvi 36 + - + - - - - - HIV
15 Mary Vasantha 45 + - + - + + - - DM WART Yes S S S S S R R
16 Mala 36 + - + - - - - - HIV/OC Yes Yes S R S S S S S
17 Palani Ammal 50 + - + - - - - - HIV BV CN
18 Thilagavathy 35 + - + - - - - - HIV Yes Yes S R R S R S S
19 Sermakani. Sekar 47 + - + - - - - - HIV HSV Yes Yes S S S S S R R
20 petchiammal 53 + - + + - - - - DM TV/W Yes CN S S R S S R R
21 Shanmugathai 45 + - + - - - - - Yes S R R S S S R
22 Vijayalakshmi 51 + - + - - - - - DM CN
23 Bagiyalakshmi 27 + - + - - - - - Yes S S R S S S R
24 Thamarai Selvi 40 + - + - - + - - DM/AB Yes CN S S S R S R R
25 Jebaral 45 + - + - - - - - Yes S S S S S R R
26 Vasantha 30 + - + - - - - - TV Yes S S S S S R R
27 Mallika 26 + - + - - - - - HIV Yes S S R S S R R
28 Latha 41 + - + - - - - - HIV CN R S S S S S R
29 Nithyalaksmi 28 + - + - - - - - HIV/OC Yes R R R S S S R
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30 Amutha 27 + - + - - - - - HIV Yes R S S R S S R
31 Mary Stella 34 + - + - - - - - HIV Yes CN
32 Boomari 42 + - + - - - - - HIV/OC CN
33 Shanmuga Sundari 51 + - + + - - + - DM HSV Yes S S S S R R R
34 Muneeswari 23 + - + - - - - - HIV Yes CN
35 Rajalakshmi 45 + + - - - - - - HIV CN
36 Sermakani. V 29 + + - - - - - - HIV Yes S S S R S S R
37 Mariammal. M 38 + + - - - - - - CN
38 Priya 22 + - + + - - - - Yes R R S S S S R
39 Mari Selvi 31 + + - + - - - - Yes S S S S S R R
40 Kala 33 + - + + - - + + HIV Yes Yes S S S S S R R
41 Katharpath 35 + - + - - - - - IM Dr Yes S S S S S R R
42 petchiamml 37 + + - - - - - - HIV CN
43 Selvi Durai 35 + - + - - - - - HIV Yes S S R S S R R
44 Shanthi Mariappan 42 + - + - - - - - Yes S R R S R R S
45 Muthu Kalaiyarasi 32 + - + - - - - - Yes CN
46 Sri Seethalakshmi 29 + - + - - - - - Yes R S S S S S R
47 Vasanthi 51 + - + - - - - - IM Dr Yes S S S S R R R
48 Nagomi 33 + + - - - - - - HIV/OC Yes S S S S S S S
49 Shanthi Thangaraj 34 + - + - - - - - DM Yes S S S S S S S
50 Shenbagavalli 37 + - + - - - - - HIV/OC/AB Yes Yes S S S S S R R
51 Mariammal Serva 38 + - + - - - - - CN
52 Ravathi 26 + - + - - - - - HIV CN
53 Roselin 29 + + - - - - - - HIV/OC/AB Yes S R S S R R S
54 lakshmi 45 + + - - - - - - AB BV CN
55 Vellairose 25 + - + - - - + - IUCD Yes R R R S S S R
56 Nabisha 29 + - + + - - + - AB Yes R S R S R R R
57 Jyothi 40 + - + - - - - - HIV CN
58 Devi 28 + - + - - - - - CN
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59 Mari 33 + - + - - - - - HIV Yes S S S S S S S
60 Velammal 34 + + - + - - - - DM Yes S R S S S S S
61 Rani 20 + + - - - - - - IUCD Yes Yes S S S S S S S
62 Sumathi 30 + - + - - - - - HIV CN
63 Pappa 37 + - + - - - + - HIV/AB WART CN
64 Mariselvam 23 + - + - - - - - CN
65 Packiam 35 + - + - - - + - HIV CN
66 Velthai 37 + - + - - - - - HIV/OC Yes S S S S S S S
67 Arokia Selvi 46 + + - - - - - - PID CN
68 mari 35 + + - - - - - - HIV Yes S S S S S S S
69 Mary Jesintha 42 + + - - - - - - Yes S S S S S S S
70 Arasammal 43 + - + - - - - - HIV/OC Yes S S S S S S S
71 Indira 36 + - + - - - - - BV Yes S S S S S S S
72 Jebaseela 21 + - + - - - - - HIV Yes S S S S S S S
73 Malar Vizhi 31 + - + - - - - - HIV CN R S R S R S R
74 Selvi. S 36 + - + - - - - - HIV HSV CN
75 Kalyani 38 + - + - - - - - CN
76 Backya Lakshmi 33 + - + - - - - - HIV Yes S S S S S S S
77 Sindhu kumari 28 + - + - - - - - Yes S R S S S S S
78 Epsibulah 35 + - + - - - - - AB Yes S R S S S S S
79 Ganga Lakshmi 44 + - + - - - - - HIV BV Yes S R S S S S S
80 Mariammal. C 30 + + - - - - - - AB Yes S S S R S S R
